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ABSTRACT 
 
 
   
 There are approximately one million hip and knee replacements each year in the 
United States alone and over 70% are cemented for stabilization.  The number of these 
replacements is expected to rise to 3.5 million per year by 2030 and result in an estimated 
several fold increase of the current global market of a billion to multi-billion dollars over 
the next fifteen years.  The current commercially available polymethyl methacrylate 
(PMMA) based bone cements have been used since the 1960’s with little change to their 
composition.  They provide strength and longevity for total joint replacements, however 
they are not without their disadvantages.  Issues such as polymerization shrinkage, high 
curing temperatures, and component toxicity have been reported.  In order to address 
these problems, we replaced the methacrylate-based resin with a silorane-based system, 
which are novel monomers previously used for dental composites.  Our goal is to develop 
"#!
a new bone cement that would have handling times between 10 – 20 min, curing 
temperatures under 45 °C, good mechanical strength, and biocompatibility.  An important 
part of this effort centered on the identification and investigation of silorane initiation 
systems, which can be tailored for specific uses including internal bone cements.  The 
initial screening process utilized the neat resin system followed by differing formulations 
including modified and unmodified fillers.  The tests were based in part on the ISO 
standard 5833 used for acrylic resin cements and included exothermicity, degree of cure, 
biocompatibility, and mechanical strength.  From these studies, we identified alternative 
bone cement formulations, which met or exceeded our desired properties as compared to 
commercially available bone cement. 
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CHAPTER 1 
INTRODUCTION TO BONE CEMENTS 
 
 
 
Current Needs 
Each year there are over one million total hip and total knee replacements 
performed in the United States alone.1  This number is expected to continue to rise due to 
the aging population.2  In addition, the average age of patients is getting younger, 
especially for knee replacements, due to more wear and tear from sports injuries. By 
2030, it is estimated that the number of total hip replacements in the US will grow to over 
550,000, which is an increase of 174%.  For total knee replacements, the numbers are 
estimated to climb by 673%, from 450,000 surgeries in 2005 to 3.48 million surgeries per 
year by 2030.  However, these numbers only take into account new surgeries and not 
revisions.3  Furthermore, while there are some cementless options, cemented 
replacements are more common and have better health outcomes such as earlier weight-
bearing and less pain.2,4  Therefore, the development of new and improved bone cements 
is still of great interest both on the commercial and academic levels. 
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History of Bone Cements 
In general, bone cements are biomaterials that are used for device fixation in knee and hip 
replacements as well as other total joint replacements (TJR). They have also been used in 
tumor surgeries, percutaneous vertebroplasty, spacers, and antibiotic beads.5  Bone 
cements, which are used for joint replacement, lack adhesive properties.  Instead, they 
hold the implant tightly against the bone and function as a space filler.  On an interface 
level, these cements mechanically interlock a surgically implanted prosthesis with the 
irregular surface of the bone while improving the prosthesis-cement-bone system’s load 
carrying capacity by the cement’s ability to transfer the load from the prosthesis to the 
bone.5,6 7   
One of the first total knee prostheses was performed by Themistolke Gluck in 
1870, using rosin and plaster to cement an ivory prosthesis.6  Today, commercially 
available bone cements are mainly comprised of methyl methacrylate and 
polymethylmethacrylate (PMMA).  PMMA has been available since 1843 and was first 
used in a biomaterial for dental applications around 1936.8  The era of modern PMMA 
bone cements began with Degussa’s and Kulzer’s patent in 1943, which utilized a tertiary 
amine to initiate the polymerization of methyl methacrylate at room temperature.6  In 
1958, Sir John Charnley developed a PMMA bone cement capable of anchoring 
implants.6,8  He attached an acrylic cup to the femoral head as well as cementing the 
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metallic implant in the femur using a PMMA bone cement.  Since the 1970s, there has 
been little, if any change in the general composition of bone cements.   
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Bone Cement Components 
Bone cements are comprised of three main components, the monomer, the 
initiation system, and fillers, all with an appropriate shelf life.  The resin is comprised of 
monomers and the initiator system.  Upon polymerization, an optimal resin should have 
low volumetric shrinkage, low generated heat , and little or no toxicity.  The filler 
components should have compatible chemistry with the resin.9  The resulting composite 
material should have all of the properties of the ideal resin plus appropriate mechanical 
properties. 
In joint replacement surgeries, there are over 30 commercial PMMA bone 
cements available, and most of them have similar compositions.2  They are normally 
packaged as a two-phase system, a powder and a liquid, both of which are mainly 
comprised of methacrylates.  The powdered portion contains pre-polymerized 
polymethylmethacrylate (PMMA) beads, a radiopacifier, and an initiator.  The liquid 
portion contains methyl methacrylate monomer, an accelerator, and an inhibitor (Table 
1.1).2  The radiopacifier, typically barium sulfate or zirconium dioxide, is visible in X-
rays, which is important for surgical purposes.  The accelerator, N,N-dimethyl-p-
toluidine (DMPT), is used to promote the initiation of the reaction by generating free 
radicals from decomposition of the initiator, benzoyl peroxide.8  The inhibitor 
(hydroquinone) protects the cement against self-polymerization due to light or heat 
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during storage by acting as a free radical trap.  Each component is discussed in more 
detail in the monomer, initiation, and filler sections of this chapter. 
 
 
Table 1.1: Typical components of commercial bone cements.2 
FUNCTION Component (industry range in total wt%) 
RESIN Methyl methacrylate (1, 32.3-33%) 
FILLER Pre-polymerized PMMA beads (2, 55.3-66%) 
RADIOPACIFIER Barium sulfate or zirconium dioxide (6-10%) 
ACCELERATOR N,N-dimethyl-p-toluidine (DMPT, 3, 0.13-0.93%) 
INITIATOR Benzoyl peroxide (BPO, 4, 0.5-1.73%) 
INHIBITOR Hydroquinone  (5, 5-25 ppm) 
 
 
Figure 1.1: Structures of bone cement components: methyl methacrylate (1), PMMA (2), 
DMPT (3), BPO (4), and hydroquinone (5). 
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Drawbacks of PMMA Bone Cement 
PMMA is used in commercial bone cements because of its strength and longevity in total 
joint replacements.2  However, there are still many drawbacks with current cements, 
including toxicity of the monomers, toxicity of the accelerator, high curing temperatures, 
and polymerization shrinkage.  Incomplete curing of the cement leads to unpolymerized 
monomers, which can leach into the body.  These monomers can cause hypotension, 
inflammation, and tissue irritation, as well as changes in liver function.10  Due to the 
volatility of the methacrylate monomer, exposure poses similar health risks in its day-to-
day usage in the surgical theater.11  High concentrations of the residual accelerator, 
DMPT (3), have been found in cement from hip replacements, which were removed after 
10 years of surgery.  Furthermore, DMPT presents a serious health issue because of its 
cytotoxicity in combination with possible long-term leaching.  Additionally, the high heat 
of the polymerization may reach temperatures greater than 70 °C.2,12  The curing heat can 
cause necrosis of the surrounding bone and tissue.  Finally, the resulting polymerization 
shrinkage is another serious problem.  Depending on the method of mixing (e.g., hand or 
vacuum), the volumetric shrinkage can range between 1-8%,13,14  which can lead to gaps 
between the implant and cement, as well as between the cement and bone.  Shrinkage, 
along with poor integration with the bone, leads to loosening of the implant and the need 
for surgical revision.13  
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Previous Alternatives 
Due to all the previously mentioned problems and the increase in total joint 
replacements, there is a need for a better or alternative bone cement—but one that would 
address the drawbacks of current commercially available cement.  Previous research 
focused on the inertness and thus lack of interaction of the cement with the bone, the 
accelerator, toxicity of the components, and the resulting high curing temperatures.  Most 
of this research centered on making small adjustments to the PMMA formulation, such as 
substitution or modification of the fillers rather than radically changing the cement’s 
formulation.2   
In order to address the issue of inertness, the addition of bioactive agents such as 
hydroxyapatite (HA) was proposed.  While there was some improvement with the 
maximum exotherm, there was no bonding between the HA and the PMMA.  Therefore, 
there was an increase of water absorption, which would result in the initiation of 
fractures.2   For the toxicity of the DMPT (3) issue, studies were performed with respect 
to the decrease in the amount of DMPT or alternative accelerators.  When less DMPT 
was used, the resulting exotherm was lower but it resulted in longer setting times.  There 
were no observable advantages when the accelerator was changed from DMPT.2   
In an attempt to address the drawback of high curing temperatures, additives were 
added to the liquid monomer (methyl methacrylate, 1). They included co-monomers such 
as N,N-diethylaminoethyl methacrylate (DEAMA, 6), methacrylic acid (7), and p-N,N-
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diethylaminobenzyl methacrylate (DEABMA, 8).2  Resins that incorporated aromatic 
monomers (e.g., DEABMA) had higher hydrophilicity, shorter setting times, and better 
mechanical properties compared to those with the aliphatic co-monomers (e.g., 
DEAMA).  However, on average, all of the additive systems, had higher maximum 
exotherms, lower compressive strength, and consistently higher residual monomer 
content as compared to commercially available cement.2  Because of these results, the 
addition of a co-monomer was not an advantageous alternative.   
 
 
Figure 1.2: Structures of co-monomer additives: DEAMA (6), methacrylic acid (7), and 
DEABMA (8). 
 
 
 
 
In order to improve the cement’s adhesion to the bone and the implant, crosslinking 
agents were investigated.  These compounds were dimethacrylates, which contain more 
than one “active” unit and would potentially result in a polymer with higher strength.  
Examples of these additives include triethylene glycol dimethacrylate (TEGDMA, 9), 
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ethylene glycol dimethacrylate (EGDMA, 10), and poly(ethylene glycol) dimethacrylate 
(PEGDMA, 11)  Unfortunately, there was no increase in mechanical strength upon the 
addition of the crosslinkers.2  In both of these additive approaches, methacrylates were 
used but they did not address the toxicity associated with residual monomer. 
 
 
Figure 1.3: Structures of crosslinking additives: TEGDMA (9), EGDMA (10), and 
PEGDMA (11). 
 
 
 
 
Since there was still an issue of toxicity and strength, other non-PMMA 
alternatives were investigated.  Two such examples were the replacement of PMMA with  
glass polyalkenoate (ionomer) cements (GPCs) and calcium phosphate cements (CPCs).2  
GPCs were first introduced by Kent and Wilson in 1970.15,16  The GPC-based cements 
are two phase systems, typically consisting of an acidic polymer solution, poly(acrylic 
acid), and a basic glass powder, usually calcium fluoroaluminosilicate.15  When they are 
combined, neutralization occurs, and the material hardens, during which process fluoride 
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ions are released.16  The fluoride release, along with good biocompatibility, has led to the 
use of GPCs in dentistry as dental fillings.15,16   
In the 1980s, Brown and Chow developed the first CPCs.8  Typically, CPCs are 
also a two-phase system with one or more calcium phosphate compounds as the solid 
phase, and phosphate-containing solution or water with an additive, such as alginate or 
succinate, as the liquid portion.17,18  When the liquid phase becomes saturated, crystals 
precipitate, and their entanglement leads to the hardening of the cement.17  CPCs are 
biocompatible, bioactive, and biodegradable; however, when tested they yielded poor 
mechanical strength.18  Because of this drawback, CPCs are mostly used as bone 
substitutes or grafts in craniofacial applications.17,18  Both GPCs and CPCs are not ideal 
cements for joint fixation.  
In order to fully understand how to improve a bone cement, each of the three main 
components, the monomers, initiation system, and fillers, need to be investigated.  Since 
the type of monomers dictates the initiation system used, the monomers will be the first 
components researched.  The monomers that are currently used in commercial bone 
cement, namely methacrylates, and then possible alternatives, such as alkenes, siloranes 
and oxiranes, were examined.  After the monomers, initiation for the various monomer 
types was investigated.
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Monomers: Methacrylates, Alkenes, Oxiranes, and Siloranes 
As mentioned previously, bone cements are mainly comprised of methacrylates.  
The structure contains contain a methyl group attached to the ! carbon (C"=C!(CH3)-
COOR), and is a methyl ester of the acrylate (Figure 1.4).19  Methacrylates are not only 
used in commercial bone cements but also in textiles, paints, plastics, and other 
biomaterials.19  In current use within the health care field, there are commercial dental 
composites, such as Filtek™ Z250, bone cements, such as Simplex® P, contact lenses, 
microcapsules for drugs, and dialysis membranes.8   
 
 
Figure 1.4: Structure of methyl methacrylate (1). 
 
 
 
Alkenes are another category of monomers that undergo free radical 
polymerization and contain at least one π bond between two sp2-hybridized carbons.20  
While they undergo many different reactions, including cationic and free radical 
reactions, (e.g., allylic halogenation), the polymerization of alkene monomers has 
O
O!
"
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produced many useful polymers.  Some of the more familiar materials are 
poly(tetrafluoroethylene), (Teflon®, 12), polystyrene (13), poly(vinyl chloride) (PVC, 
14), and polyethylene (15) (Figure 1.5, where only the simplest repeated unit is depicted). 
 
 
Figure 1.5 a-d:  Common alkene based polymers: Teflon® (12), polystyrene (13), PVC 
(14), and polyethylene (15). 
 
 
 
 
The standard free radical process for monomer units (e.g., alkenes and acrylates) 
is comprised of three steps: initiation, propagation, and termination.20  The initiation step 
is one in which a radical is generated using heat, light, and/or chemical initiation.  It does 
not involve the monomer, but typically an initiator radical.  The propagation step is the 
reaction of at least one radical with a monomer to expand the polymer chain and results 
in another radical generated.  This monomer radical reacts with another monomer to 
n
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continue the process (Scheme 1.1).  The final step is termination, in which two radicals 
combine, thus “terminating ” the chain reaction.20   
 
 
Scheme 1.1: Free radical polymerization propagation step. 
 
 
 
Oxiranes 
Oxiranes, also known as epoxides, are three-membered rings containing an 
oxygen and two carbons.  They are used in adhesives, paints, coatings, and more recently 
dental impression materials.21  Dow’s CYRACURE™ UVR-6110 ((7-
oxabicyclo[4.1.0]heptan-3-yl)methyl-7-oxabicyclo[4.1.0]heptane-3-carboxylate, 16), is 
an example of an epoxy resin that is used as a casting resin and UV resistant decorative 
coating for metals (Figure 1.6).22  Oxiranes normally undergo cationic ring opening 
polymerization, which requires an initiator but is not limited to acids.  An example 
polymerization scheme for cyclohexene oxide is depicted in Scheme 1.2.   
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Figure 1.6: Structure of UVR-6110 (16). 
 
 
 
Scheme 1.2: Oxirane cationic polymerization scheme. 
 
 
 
 
Siloranes 
Another class of monomers is one that contains both oxirane and siloxane 
functional groups, siloranes (disiloxane, 18).  A siloxane compound contains a silicon – 
oxygen bond (18) (Figure 1.7).23   1,3-Bis(2-(7-oxabicyclo[4.1.0]heptan-3-yl)ethyl)-
1,1,3,3-tetramethyldisiloxane (silorane, 19) undergoes cationic ring opening 
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polymerization at the oxirane unit and is one component of a commercially available 
dental composite distributed by 3M ESPE, and called Filtek™ LS.24  
 
 
Figure 1.7: Structures of oxirane (17), a siloxane (disiloxane, 18), and silorane (19). 
 
 
 
In an attempt to reduce polymerization shrinkage of dental composites, siloranes were 
first investigated as an alternative to the current methacrylate-based composites.  
Polymerization shrinkage is problematic because it can lead to small spaces between the 
material and the tooth, leading to loosening of the filling and even failure.23  For example, 
neat methyl methacrylate resins have been shown to have shrunk up to 22 vol%,25 
whereas the methacrylate-based composite, Filtek™ Z250, resulted in around 2% 
volumetric shrinkage.  On the other hand, the volumetric shrinkage of a silorane 
composite was less than 1%, which is a significant difference compared to the neat 
resin.23  The reduced methacrylate polymerization shrinkage was due to the bonding 
change from a carbon-carbon double bond into a single bond with a neighboring 
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monomer.26  For siloranes, their large bulky size, along with the oxirane ring opening 
during polymerization, resulted in less shrinkage. 
As mentioned previously, biomaterials are comprised of monomers, an initiation 
system, and fillers.  Methacrylates, alkenes, oxiranes, and siloranes have been discussed 
and used in biomaterial resin.  While they all have shortcomings, the initiation system is 
important for the determination of a possible commercial biomaterial. 
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Initiation   
The initiators fall into two categories: “on demand” curing,32 commonly referred 
to as photo- or light-induced  initiators and “immediate curing,” also labeled as chemical 
curing.  For the light-induced curing systems, they are commonly binary or ternary 
systems.  A binary photoinitiation system consists of a light absorbing photosensitizer, 
which absorbs light to initiate a reaction, and an electron donor, which propagates the 
reaction.  A ternary system includes the addition of an accelerator.  A typical 
photosensitizer is normally a dye or ketone (Figures 1.8 and 1.9). Examples of dyes 
include substituted azines (R2C=N-N=CR2, compounds derived from the reaction of 
hydrazine with a ketones or aldehydes, 1,4-diazine 20), thiazoles (heteroaromatic 
compounds containing a sulfur and nitrogen atom, thiazole (21)), and xanthenes  
(xanthene, 22).  However, the preferred photosensitizer is a ketone, such as a 
monoketone, α-diketone, or ketocoumarin.  A few examples of these types of ketones are 
benzophenone (23), anthraquinone (24), camphorquinone (25), and 3-acetylcoumarin 
(26) (Figure 1.9).28-30  After the photosensitizer is irradiated, the excited species has a 
short lifetime in which to react with the monomer to initiate polymerization, leading to 
slow rates of polymerization when used alone.  In the case of camphorquinone, there was 
only an 18.3% degree of conversion for a methacrylate-base resin after 60 sec of 
irradiation.31  Due to the slow reaction time there is need for an additional component, a 
proton donor. 
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Figure 1.8: Examples of photosensitizer – dyes: 1,4-diazene (20), thiazole (21), and 
xanthene (22). 
 
 
 
Figure 1.9: Examples of photosensitizer – ketones: benzophenone (23), anthraquinone 
(24), camphorquinone (25), and 3-acetylcoumarin (26).  
 
 
 
Disubstituted amines are common proton donors in photoinitiation systems (Figure 1.10).  
A few examples of these reaction promoters are ethyl p-dimethylaminobenzoate 
(EDMAB, 27), 4,4'-bis(diethylamino)benzophenone (BDEAB, 28), and 2-
dimethylaminoethyl methacrylate (DMAEMA, 29).30,32  These compounds react with the 
excited photosensitizers to generate the radicals needed for polymerization.  With the 
addition of EDMAB to camphorquinone, there was in increase in the degree of 
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conversion for a methacrylate-base resin to 55% after 60 s of irradiation compared to 
18% with camphorquinone alone.31 
 
 
Figure 1.10: Examples of proton donors: EDMAB (27), BDEAB (28), and DMAEMA 
(29). 
 
 
 
 In the case of a ternary photoinitiation system, there is the addition of an 
accelerator, which is usually a photoacid.23  Photoacids are compounds that generate an 
acid after irradiation.  In the case of light-induced initiation systems, the photoacids are 
typically onium salts, such as (4-n-octyloxyphenyl)phenyliodonium 
hexafluoroantimonate (30) and [4-[(2-hydroxytetradecyl)oxy]phenyl]phenyliodonium 
hexafluoroantimonate (31) (Figure 1.11).30,33   For onium salts, alone they are activated 
by light below 300 nm, generating a reactive aryliodo radical-cation.31  This is typically 
done by using a UV light source; however, that would not be suitable for applications in 
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health-related fields.  When used in conjunction with a visible light photosensitizer and 
proton donor, the onium salt will decompose in the visible light range, yielding the 
reactive radical-cation.  The addition of an onium salt to the binary system of 
camphorquinone and EDMAB increased the rate of polymerization for a methacrylate-
based resin from 1.65% to 2.73% per s.31 
 
 
Figure 1.11: Onium salts 30 and 31.   
 
 
 
These ternary light-cure systems can be used for both free radical and cationic 
polymerization.  For methacrylate dental composites, an excited species is produced from 
the photosensitizer, camphorquinone, after irradiation with a dental lamp with a 
wavelength of 470 nm.   In this case, the tertiary amine is responsible for the hydrogen 
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transfer reaction generating the radical.23,31,34,35  The reaction mechanism for the radical 
generation is depicted in Scheme 1.3 using camphorquinone and EDMAB.  Once the 
initial radicals have been formed, the polymerization reaction can begin (see Scheme 
1.1).  In cationic systems, after irradiation, the excited photosensitizer reacts with the 
onium salt leading to a radical-ion species.31  When this radical-ion species is reduced, it 
is the Lewis or Brønsted acid produced from the onium salt that initiates the cationic 
polymerization.33,36   
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
Scheme 1.3: Radical formation during light initiation. 
 
 
 
The conjugate base produced in this conversion plays no role in the photochemistry 
cycle; however, a weak nucleophile is required so as not to prematurely terminate the 
polymerization reaction.37  
While light initiation is acceptable for dental composites, light initiation is not 
feasible for other biomaterials, such as bone cements.  Instead, they undergo chemically 
initiated free radical polymerization, where a chemical, not light, generates the radical.  
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In a typical bone cement, an amine accelerator, DMPT, decomposes the initiator, benzoyl 
peroxide (BPO), to generate the radical.8,38  The mechanism for the free radical 
polymerization of methyl methacrylate, which is initiated by using this process, is 
depicted in Scheme 1.4. 
 
 
Scheme 1.4: Chemically initiated free radical polymerization of methyl methacrylate. 
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In the case of oxiranes, extreme conditions, such as harsh catalysts and /or high 
heat applications, are frequently used in the chemical curing process for industrial 
settings.  Typical laboratory conditions include high temperatures (e.g., temperatures 
greater than 80 °C), prolonged reaction times, and/or a 1:1 ratio of catalyst to monomer 
for complete conversion to product .28  These conditions are definitely not suitable for a 
biomaterial cured internally. 
For classical chemical initiators (e.g., Lewis or Brønsted acids), almost immediate 
curing occurs when the initiation ion is released during the dissociation of the initiator in 
the monomer system.39  Acids used for polymerization fall in to the categories of 
Brønsted, strong, weak , super,40 and Lewis41 acids.  Brønsted acids are proton donors 
and the terms “weak” and “strong” acids refer to an acid’s ability to dissociate to ions in 
water.   Strong acids completely dissociate in water, while weak acids only partially 
dissociate.  Therefore, stronger acids have larger acid-dissociation equilibrium constants, 
Ka, than weak acids.  An example of a typical strong acid is hydrochloric acid (HCl, 32), 
which has a Ka of 1 x 103, while acetic acid (CH3COOH, 33) is a weak acid with a Ka of 
1.8 x 10-5 (Figure 1.12 a-b).20  Acid strength is more commonly referred to as pKa, the 
negative logarithm of the acid-dissociation constant.  In regards to pKa, smaller values 
equate to stronger acids.  For HCl, the pKa is -8, whereas  CH3COOH has a pKa of 4.8.20  
Acids that are 100 times stronger than sulfuric acid (pKa = -3)20 belong to the category of 
“super” acids.40  An example of a super acid is hexafluorophosphoric acid (HPF6, 34).  
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Rather than limiting an acid to a proton donor, compounds that can accept a pair of 
electrons are Lewis acids.  Examples include aluminum chloride (AlCl3, 35), iron (III) 
chloride (FeCl3, 36), and boron trifluoride (BF3, 37) (Figure 1.12).  These particular acids 
are often used in Friedel-Crafts alkylations and acylations, which are important 
electrophilic aromatic substitution reactions.20  In the reaction of benzene with acetyl 
chloride, a Lewis acid catalyst, aluminum chloride, is used, and the halogen becomes a 
stronger electrophile.  
 
 
Figure 1.12: Example of acids: HCl (32), CH3CO2H (33), HPF6 (34), AlCl3 (35), FeCl3 
(36), and BF3 (37). 
 
 
 
While these acids are quite effective in polymerization20  and Friedel-Craft reactions, 
there are several drawbacks.  In the case of Friedel-Craft acylation, the Lewis acid is not 
a true acid catalyst because it complexes with the carbonyl group of the product.   In 
some cases, heat is required for the reaction to occur but it is generally an exothermic 
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reaction.20  These are limitations for their use as initiators in biomaterials because 
stoichiometric requirements, toxicity, sensitivity, and exothermicity can cause cell 
necrosis.2,12,42,43   
Since the early 1980s, a relatively new subgroup of redox initiators has been 
investigated.44,45  This category is comprised of noble metal complexes, such as platinum, 
palladium, and rhodium catalysts; a reducing agent, such as an organosilane; and an 
oxidizing agent, such as an onium salt.  The original applications for these organometallic 
complexes were developed for synthetic transformations, which include hydrosilylation 
(platinum-based Lamoreaux’s catalyst, rhodium-based Wilkinson’s catalyst) and olefin 
metathesis (ruthenium-based Grubbs’ catalyst) reactions.44-46  A example of 
hydrosilylation is the reaction of pent-1-ene and dimethyl(phenyl)silane with Wilkinson’s 
catalyst producing dimethyl(pentyl)(phenyl)silane (Scheme 1.5).47  Grubbs’ catalyst is 
used in the olefin metathesis reaction of 4-allyl-2-methoxyphenol and (Z)-but-2-ene-1,4-
diol with (E)-4-(4-hydroxybut-2-en-1-yl)-2-methoxyphenol as the product (Scheme 
1.6).48  The onium salts have previously been used as photoacids in light initiation 
systems, and more recently, they have been employed for chemical initiation.30,33  These 
redox initiators are used in catalytic amounts, which is advantageous for a biomaterial.  
Polymerization studies using these redox initiation systems have proceeded rapidly with 
high reaction exotherms.49,50  An example of such is the polymerization of 4-
vinylcyclohexene-1,2-oxide with Lamoreaux’s catalyst and an iodonium salt which 
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polymerized almost spontaneously with a temperature reaching 258 °C.49  While this 
result is not an issue in synthetic methodology, this, along with the possible high toxicity 
of the organometallic catalysts, would be problematic for its use in health-related 
applications.50,51 
 
 
Scheme 1.5: Example hydrosilylation reaction. 
 
 
 
Scheme 1.6: Example of olefin metathesis reaction. 
 
 
 
In the development of initiation systems, there are several different factors to 
consider, including exothermicity, toxicity of acid, and handling times.  In order to 
“tailor” these systems to have the desired properties required for that application, 
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inhibitors can be used in conjunction with the initiators. They can restrict or delay the 
polymerization reaction by consuming any heat or light generated by the radical and 
prohibiting it from initiating polymerization.34  Once the inhibitor is completely 
consumed, the initiators are free to start the reaction.  An example of a free radical 
inhibitor is hydroquinone (5), which is used in commercial bone cements (Figure 1.13).  
Usually used in ppm quantities, the hydroquinone is first utilized to prevent the methyl 
methacrylate monomer from self-polymerizing during storage due to light or heat, which 
results in an increased shelf life.  The addition of 5 extends the mixing time of the liquid 
and powdered portions of the bone cement.  Once all of the inhibitor has been consumed, 
the remaining radicals can then begin the polymerization of the monomers.  
Hydroquinone is an excellent free radical inhibitor because of its high affinity for free 
radicals.  It is able to donate a proton to a free radical species.  The radical becomes 
trapped in 5 due to its resonance structures (Scheme 1.7).  
 
 
Scheme 1.7: Hydroquinone as a free radical trap. 
 
O
O
H
R
O
O
RH
H H
H
H
H
H
H
H H
H
O
OH
H
H H
H
O
OH
H
H H
H
O
OH
H
H H
H
+
 46 
There are several other compounds belonging to the hydroquinone class including 
2,6-bis(1,1-dimethylethyl)-4-methylphenol (BHT, 38) and mixture of  2-tert-butyl-4-
hydroxyanisole (!15%)  and 3-tert-butyl-4-hydroxyanisole, called BHA ("85%) (39) 
(Figure 1.13).52  Both BHT and BHA are commonly used as food additives to extend the 
shelf life of bread and oils as well as cosmetics.52,53  In the case of cationic 
polymerization, strong bases, diols, and crown-ethers, have been also known to inhibit 
polymerization,54,55 the same way as the free radical inhibitors, but with ions.  Such is the 
case of 12-crown-4 inhibiting the polymerization of 3,4-epoxy cyclohexyl methyl-3,4-
epoxy cyclohexyl carboxylate.55  The crown ether traps a proton keeping it from the 
polymerization reaction (Scheme 1.8).  
 
 
Figure 1.13: Structures of free radical polymerization inhibitors: hydroquinone (5), BHT 
(38), and BHA (39). 
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Scheme 1.8: Crown Ether as a proton trap. 
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Fillers 
The last of the three main bone cement components is the filler.  When choosing a 
filler, chemical compatibility and a similar refractive index are just two of the 
characteristics that need to be considered.  In order to improve additional properties of 
the resin, fillers are added to reduce polymerization shrinkage and provide optimal 
mechanical properties, such as flexural strength and flexural modulus.  Usually, an 
increase in filler equates to an improvement in strength, but this is dependent on a good 
filler-resin interaction.35 Certain fillers can also be incorporated as radiopacifiers, which 
are added to a composition or formulation so as to make the material visible in diagnostic 
imaging (e.g., x-rays) as well as allowing for differentiation between the cement, bone, 
and implant.  They are typically heavy inorganic metal salts, such as barium sulfate 
(BaSO4), bismuth oxide (Bi2O3), zirconium oxide (ZrO2), and yttrium (III) oxide 
(Y2O3).56  These compounds are radiopaque because of their high density, which is due to 
the high atomic mass of the elements.56  Typical commercial bone cements use either 
barium sulfate or zirconium oxide as in the case of Simplex P.   
Fillers are essentially comprised of glass and other powders, such as polymer 
beads or nanofibers.  In dental composites, quartz and other silica-based fillers are often 
used to enhance the mechanical properties, and barium, zirconium, or other heavy metals 
are added for radiopacity.35  Bone cements, on the other hand, use pre-polymerized 
polymer beads to increase the material’s strength and either barium or zirconium to 
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ensure radiopacity.7  Depending on the application, the formulation is filled to different 
levels, which changes the viscosity of the cement.  For dental composites, the cement is 
filled from 38 – 85 wt% depending on the particle size, of which 5-15 wt% is the barium 
sulfate radiopacifier.21  In the case of typical commercial bone cements, the polymer 
beads make up the majority of the filler (55 – 60 wt%) with only 6 – 10 wt% of barium 
sulfate or zirconium dioxide.2  
In addition, the filler’s surface can be modified in order to improve the resin-filler 
interaction.  Most dental composite fillers are modified so as to reduce hydrophilicity and 
enhance filler dispersion.26   Better filler dispersion allows for higher filler loading, which 
in turn improves the properties of the matrix, resulting in a stronger material with less 
polymerization shrinkage.26.35  
 
 
Scheme 1.9: Filler modification reaction scheme. 
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The filler can be modified by a chemical reaction of the Si-O with a compatible 
monomer, which covalently bonds the monomer to the glass surface. (Scheme 1.9).  The 
rationale is that the functional interface provided by the modification may assist in 
dispersion, “homogeneity” and improved modulus.  The most common monomer used 
for this purpose in dental glasses is methacryloxypropyltrimethoxysilane (MPS, 40, 
Figure 1.14).26   
 
 
Figure 1.14: Structure of methacryloxypropyltrimethoxysilane (MPS, 40). 
 
 
 
All three components of a biomaterial formulation, monomer, initiation system, and 
filler, have now been described.  The requirements of a biomaterial, more specifically a 
bone cement, and the assessments that would be used to evaluate that material, are 
discussed in the next sections. 
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Properties of Bone Cement and Standard Testing 
There is a set of desired properties that are required for the bone cement 
formulations, including handling and polymerization times, heat of polymerization, 
flexural strength, and flexural modulus.   
 
 
Table 1.2: Desired properties of bone cement. 
  ISO 5833 Standard
57 Desired properties 
Exothermicity (°C) !90 !45 
Handling time (min) 3-15 !20 
Flexural modulus (GPa) "1.8 "1.8 
Flexural strength (MPa) "50 "50 
Compressive strength (MPa) "70 "70 
Pull out strength – mimic (MPa) n/a "4.5 
Pull out strength – ex vivo (MPa) n/a "4.5 
Pull out strength – in vivo (MPa) n/a "4.5 
Cytotoxicity (% cell death) n/a !20% 
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The results of our studies were compared to the standards listed in the International 
Standard for “Implants for surgery – Acrylic resin cements” ISO 5833 (Table 1.2).57  In 
addition to the ISO standard, the other parameters that were investigated include the 
degree of conversion, biocompatibility, and finally the pull out strength. 
For the determination of the polymerization completion or “hardness”, the 
Gillmore Needle Test (GNT) or a penetrometer was used.  In both cases, they are used to 
determine when a material has polymerized to an appropriate hardness.  A needle or 
probe with a specific weight is placed on the top of a sample.  Then, observations of the 
ability of the sample to support the weight of the probe and any visible defects to the 
surface are made.  For the GNT, a common test for concrete and dental materials, two 
needles with different weights are used to determine the setting time of a material.35  On 
the other hand, a penetrometer is an electric device and is used for testing soil 
compaction.  The GNT was chosen because of its ease of use, and because it requires less 
material than a penetrometer. For this testing, the one-lb. and #-lb needles were chosen.  
The one-lb. needle was placed on the sample and then removed.  If no mark was 
observed, the sample passed.  But if a mark or indentation was made, then the sample 
failed. 
Exothermicity is the heat generated during the polymerization of a sample.  When 
a material is used in the body, high polymerization temperatures can cause cell and tissue 
necrosis.2,12,42  Exotherms have been measured with something as simple a thermometer.  
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A thermocouple is more commonly used, and it can record the temperature profile of the 
reaction.  For the testing of exothermicity in this dissertation, a thermocouple was chosen, 
and the samples were standardized for reproducibility and accuracy.  In ISO 5833, there 
is a defined mold, however a smaller one was developed to limit the amount of wasted 
resin.  The mold was a Delrin® ring (9.9 mm diameter, 0.7 mm thick) taped to a glass 
slide.  The tip of the thermocouple was then placed inside the ring and secured by tape.  
The sample was mixed and placed in the ring completely surrounding the thermocouple, 
which measured the temperatures.  From the resulting graph, the maximum exotherm (the 
highest point on the graph) and the rate of polymerization (where the graph flattens out 
after the peak) were determined.  See Figure 1.15 for an example plot.   
 
 
Figure 1.15: Example exotherm plot.    
 54 
 
The handling or working time is the length of time a material can be manipulated 
and molded.  This time is from when the material is mixed until it becomes elastic and 
can no longer be manipulated.35  This property is important because it insures that a 
surgeon can place a material in its desired location before it completely polymerizes.  For 
this test, the amount of time between initiation and when the material began to gel or was 
too firm to be manipulated by the researcher’s hand was recorded in this dissertation.  
According to the ISO 5833 Standard,57 for bone cements, the handling time should be 
between 3 - 15 min.  For our material to pass this test, it needs to have a handling time 
between 5 - 20 min to have the desired properties. 
The flexural strength and flexural modulus are measures of the strength and 
stiffness of a material.  The ISO standard is determined using the four-point bend test, 
which is a standard mechanical test widely used for plastics, concretes, and composites.  
0 
10 
20 
30 
40 
50 
60 
70 
0 264 528 792 1056 1320 
E
xo
th
er
m
 (°
C
) 
Time (s) 
CC silorane 
PMMA bone 
cement 
 55 
With the exception of the specimen size (due to sample conservation), the ISO 5833 
guidelines were followed.  In this study, the specimen dimensions in ISO 4049 were 
used.58  A beam sample (2 x 2 x 25 mm) was held in place at four points, and then a load 
was applied to the middle of the beam until it fractured (Figure 1.16).  From the resulting 
stress-strain curve, flexural strength was determined by the maximum peak observed on 
the graph.  The flexural modulus was calculated from slope of the curve before fracture 
(Figure 1.17).      
 
Figure 1.16:  Four-point bend test. 
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Figure 1.17: Example of stress-strain curve.   
 
Compressive strength is a measure of “a material’s ability to withstand 
compressive loads without being crushed”,42 and was tested according to guidelines 
described in ISO 5833.  A cylindrical sample (6 x 12 mm) was placed in between plates 
on the mechanical tester and then a load was applied until the cylinder began to deform or 
was fractured.  The force required for failure was divided by the area of the cylinder to 
determine the compressive strength (MPa) of the material.  The compressive strength for 
our material should be greater than 70 MPa as according to the ISO 5833.57   
Fourier Transform Infrared Spectroscopy (FTIR) was used to determine the 
degree of conversion or degree of cure.  These were measured by comparing the change 
in a peak associated with polymerization (e.g., 883 cm-1, representing epoxide ring 
opening) to an unchanging peak – an internal standard reference control (e.g., 1257 cm-1, 
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assigned to the Si-O bond in the silorane ring structure).  The peak ratios were then 
calculated (and then reported as a percentage).   For this test, a Delrin washer was affixed 
to the Attenuated Total Reflectance (ATR) accessory with laboratory tape.  
Approximately 0.1 g of material was placed into the ring that was centered over the ATR 
crystal.  A baseline spectrum was collected before curing.  An example spectrum is 
depicted in Figure 1.18.  The peak label “O in ring” is the peak associated with the Si-O 
bond within the ring in the silorane and remains constant (internal standard).  The other 
labeled peak corresponds to the oxirane units of the silorane, which should decrease upon 
reaction.   
Figure 1.18: Sample FTIR spectrum for degree of conversion determination. 
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Since a biomaterial has an application for internal use, biocompatibility is an 
important property.  It is a measure of a material’s effect, positive or negative, on the 
cells and surrounding tissues.  For our testing, MLO-A5 cells were used, which are post-
osteoblast/pre-osteocyte type cells that come from the long bone of mice59 and were 
chosen because of our collaboration with Dr. Lynda Bonewald at the UMKC School of 
Dentistry. With these cells, the Trypan Blue (TB) Exclusion and MTT assays were 
utilized to determine cell death and cell viability, respectively.   Other toxicity assays are 
possible alternatives, such as other dyes like methyl violet or Evans blue.  However, for 
live cell exclusion, Trypan blue dye is the most common.  The TB assay is preferred 
because a live cell’s membrane does not allow the uptake of the dye whereas the dead 
cell does, leaving the living cells colorless and the dead cells blue.60  The MTT assay 
indicates cell viability by measuring the optical density of the purple formazan.  Viable 
cells reduce yellow 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide to 
formazan, while unviable or dead cells do not.  The higher optical density correlates to 
greater cell viability.60   
Pull out strength is how strongly an implant is held within the bone by the cement.  
Depending on the position of the failure during testing, it is a measurement of either the 
strength of the bone/cement interface or the cement/rod interface.  While there is no clear 
standard sample preparation method, typically a hole is drilled into a bone, and the 
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cement and rod are inserted.  For testing, the tip of the rod is exposed, and the entire 
sample placed into a holder and tested on a mechanical tester such as an Instron.  The 
Instron pulls the rod at a constant rate until there is a failure.61 
More details about each of these test methods can be found in the Appendix A 
(Materials and Methods).  From the collection tests mentioned previously, the proposed 
biomaterial was evaluated, and its potential use as a new and better bone cement 
determined. 
 
! %&!
Early Work 
A previous project within our collaborative research group was to investigate a 
new silorane resin, SilMix, as an alternative for dental composites.  SilMix is a 50:50 by 
weight combination of two monomers, 2,4,6,8-tetrakis(2-(7-oxabicyclo[4.1.0]heptan-3-
yl)ethyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxa-tetrasilocane (CYGEP, 41) and 
bis[2-(3{7-oxabicyclo[4.1.0]heptyl})-ethyl]methylphenyl silane (PHEPSI, 42), which 
were synthesized by Bradley Miller at UMKC. 62  Throughout the research described 
herein, it was proposed that SilMix is an excellent alternative for bone cements because 
of its promising physical properties,63,64 stability in water,65 and greater 
biocompatibility.59,66  
 
 
Figure 1.19:  CYGEP (41) and PHEPSI (42). 
 
 
O Si
O
Si
OSi
O
Si
O
O
O
O
Si
O O
41 42
! %'!
Earlier work was centered on the screening of possible fillers for use with light-
initiated SilMix.  The first level of screening was a pass/fail of polymerization for the 
individual fillers formulated with SilMix using the GNT.  If a filler passed that step, the 
biocompatibility of the formulation was studied.  The final screening was mechanical 
testing, specifically flexural strength and flexural modulus.67.68 
Once SilMix had been identified as the base resin system, the next step was the 
selection of the appropriate filler.  The screening test was the one lb. Gillmore needle test 
(GNT), pass/fail.  A variety of fillers were investigated including unmodified glass from 
MoSci Corporation (Rolla, MO) and alumina nanofibers (ANF) (Dr. Thomas Schuman at 
Missouri University of Science and Technology, MS&T) (Table 1.3 a-c).  SilMix 
samples containing a ternary light initiation system (3 wt% PIH, 1 wt% CPQ, and 0.15 
wt% EDMAB) were filled to 50 wt% with a filler.  After irradiation with a dental lamp 
for two min, the samples underwent the GNT.  With the exception of two glasses, all the 
others passed the GNT.  M7 and M8 failed to polymerize and were excluded from further 
testing.  The ANF failed at 50 wt%.  It was then tested at 10, 20, and 30 wt%s resulting in 
a failure at 30 wt%.  
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Table 1.3 a-c: Glass fillers from MoSci. 
a) 
Batch Formula 
Composition 
Filler  
Y2O3 Al2O3  SiO2  Na2O total 
DY5  15 5 80 0 100 
DY6  15 15 70 0 100 
DY7 14.25 12.25 66.5 5 100 
DY8 13.5 13.5 63 10 100 
DY9 12.75 12.75 59.5 15 100 
DY10 12 12 56 20 100 
DY11 11.25 11.25 52.5 25 100 
 
b) 
Batch Formula 
Composition 
Filler 
Li2O MgO BaO  CaO SrO Y2O3 Yb2O3 B2O3 Al2O3 SiO2 As2O3 AlF3 total 
M-1  3 2 9 0 0 3 0 58 14 8 0 3 100 
M-2  3 2 9 0 0 3 0 29 14 37 0 3 100 
M-3  3 2 9 0 0 0 3 29 14 37 0 3 100 
M-4  3 2 9 0 0 3 0 58 0 22 0 3 100 
 
c) 
Batch 
Formula 
Composition 
Filler 
Na2O K2O MgO CaO BaO TiO2 ZrO2 ZnO B2O3 Al2O3 SiO2  SO3 Fe2O3 Sb2O5 total  
M-5  0.9 0.4 8.3 0.2 0 0.1 8.8 0 0 20.9 60.4 0 0 0 100 
M-6  0.9 0 2.2 22 0 0 4.5 0 7.2 10.6 52.6 0 0 0 100 
M-7  9.8 0.4 0.6 5.9 0 0.2 21.8 0 3.1 3.8 54.4 0 0 0 100 
M-8  6 8.3 0.1 6 1.9 0 5 4.6 0 1.8 65.2 0.4 0.1 0.6 100 
M-9  5.3 6.3 0 0 0 3.6 4.9 7.4 8.1 3.6 60.8 0 0 0 100 
M-10  11.6 0.1 3.5 9.6 0 0 1.8 0 0 0.8 72.2 0.3 0.1 0 100 
M-12 0 0 0 0 29.1 0 0 0 10.5 5.9 54.5 0 0 0 100 
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DY5, M1-M4, and M12 glasses along with the ANF were selected to undergo 
surface modification by Dr. Schuman.  The glasses were selected because of their 
polymerization results as well as having a refractive index similar to that of the resin, 
SilMix.  There were five modifications that were performed with the five fillers.  A list of 
the modifications and structures are given in Table 1.4 and Figure 1.20.  All of the 
modified glasses passed the GNT at 50 wt% (Table 1.5a).  The 2-(3,4-
epoxycyclohexyl)ethyltrimethoxysilane (ECHE)-modified ANF, on the other hand, failed 
at 30 and 50 wt%s but passed at 10 and 20 wt%s (Table 1.5b).   
 
 
Table 1.4: Filler modifications (43 – 47). 
Modification Abbreviation  
3-glycidoxypropyltrimethoxysilane GP-TMS (43) 
3-methacrylpropyltrimethoxysilane MAP-TMS (44) 
2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane ECHE-TMS (45) 
[(9,9-diethyl-1,5,7,11-tetraoxaspiro[5.5]undec-3-yl)methyl]trimethoxysilane   1TOSU (46) 
[3-(9,9-diethyl-1,5,7,11-tetraoxaspiro[5.5]undec-3-yl)propyl]trimethoxysilane  3TOSU (47) 
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Figure 1.20: Structures of filler modifications (43 - 47). 
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Table 1.5 a-b:  Modified filler polymerization results. 
a) 
Filler Modification Pass/Fail: 50% filled 
M-1  ECHE Passed 
M-2  ECHE Passed 
M-3  ECHE Passed 
M-4  ECHE Passed 
M-12 ECHE Passed 
M-12 1TOSU Passed 
M-12 3TOSU Passed 
DY5  GP-TMS Passed 
DY5  ECHE-TMS Passed 
DY5  MAP-TMS Passed 
DY5  1TOSU Passed 
DY5  3TOSU Passed 
 
b) 
Modified Fillers Modification Pass/Fail      50% filled 
Pass/Fail      
10% filled 
Pass/Fail      
20% filled 
Pass/Fail      
30% filled 
Alumina 
Nanofibers ECHE Failed Passed Passed Failed 
 
 
After discussion of these results with our collaborators, it was decided to use DY5, M12, 
and the ANF for future testing. The cytotoxicity of the fillers were tested as part of the 
light-cured SilMix system and were found to be biocompatible.  More detailed 
information can be found in Dr. Jennifer Melander’s dissertation.68  
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For samples formulated with the DY5, M12, and/or ANF fillers, the flexural 
strength and flexural modulus were investigated using the four-point bend test.  The 
flexural strength and modulus were determined from the resulting stress-strain curve..  
The resins were filled to no more than 50 wt% with various combinations of the fillers.  
This limit was selected because the majority of filled biomaterials contain 40 – 84 wt% 
filler.  More details can be found in Dr. Jennifer Melander’s dissertation68 and the 
publication by Melander et al.67  In summary, it was found that incorporation of more 
than one filler in the resin did not improve either the flexural strength or flexural 
modulus.  It was determined to use either the DY5 or M12 (filled to 50 wt%) as the main 
fillers for future work. 
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Summary 
As mentioned previously, there is a growing need for an alternative bone cement 
because of the drawbacks (i.e., toxicity of the monomer and exothermicity of the 
polymerization) of the currently available commercial bone cements  The previous work 
on dental materials by our collaborators provided us with a possible resin, SilMix, which 
was investigated as an alternative formulation.   Three base fillers (DY5, M12, and ANF) 
and three surface modifications (ECHE, 1TOSU, and 3TOSU) were identified to move 
forward in our research.  After these two components were identified, the next step was 
the selection of an appropriate initiation system, which is the third and final component 
of the bone cement.  
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CHAPTER 2 
CHEMICAL AND MIXED INITIATION SYSTEMS 
 
 
 
Introduction 
The goal of this research was to develop a silorane-based bone cement alternative.  
Bone cements are composed of three components, monomer(s), initiation system, and 
filler. Since SilMix (50:50 by weight ratio of CYGEP and PHEPSI) was selected as the 
base of a bone cement alternative, our next goal was to choose an appropriate initiation 
system because a sole light initiation system is not feasible for internal use, which will be 
discussed below.   
There are four main problems with a light initiation system.  The first issue is the 
possibility of cell damage due to the wavelength of the light source required for initiation.  
Second, the heat radiating from a light source can be a problem for internal use.  Some 
light sources (e.g., 100-watt light bulb) can generate heat greater than 100 °C, which may 
cause cell and tissue necrosis.2,12,42  The third issue is the resulting depth of cure, which 
may lead to incomplete cure.  While there is normally ongoing curing or “dark cure”, the 
initial irradiation is at the surface of the material.  Therefore, thickness of the material 
and the refractive index of the filler/formulation affects the completeness and overall time 
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of cure.35 This time and depth of cure are issues in joint replacements because patients are 
required to bear weight on the new joint as soon as possible, sometimes as soon as 24 h 
post surgery.3-5  Lastly, there are logistical problems resulting from the use of a light-
initiated bone cement.  Due to the orientation and placement requirements for implants, it 
is close to impossible to use a light source internally.  A specific example results from the 
difficulty in the placement of a light source in the femur canal during hip replacement 
surgeries.  Due to these four issues resulting from light initiation requirements, an 
alternative chemical initiation system was a prerequisite for the development of silorane-
based cement.  The appropriate initiation system should meet or exceed the following 
conditions: have an appropriate handling time, generate little heat during the 
polymerization process, and maintain biocompatibility.  The handling time should be 
between 5 – 15 min to allow the surgeons time to place the material in the surgical site.  
Ideally, there should be little to no heat produced during polymerization because the heat 
may cause cell necrosis and damage to surrounding tissue. Finally, it is important that the 
biocompatibility is similar to light-cured SilMix resins so that it can be considered as a 
viable alternative to commercially available bone cements. 
In order to move forward, there were screening points for each condition before 
an initiation system would continue to be considered, which were the Gillmore needle 
test (GNT), pH, exothermicity, biocompatibility, and degree of conversion.  The initial 
screening was a GNT, which was used to determine the time to cure to “hardness”. GNT 
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and degree of conversion were points used to investigate the handling time.  If the 
formulation passed the GNT by supporting its weight for 30 sec, it was subjected to a pH 
study to determine the acidity of the material.  The acceptable pH difference was within 
0.5 units of the light-cured SilMix control.  After which, the heat of polymerization was 
investigated using a thermocouple to measure the exothermicity profile.  When the 
formulations passed the previous three screening parameters, then the biocompatibility 
and degree of conversion were determined.  Ideally, the most desirable system would 
have a low heat of polymerization, was biocompatible, and had a handling time between 
five and fifteen min.  It was determined that the pure chemical initiation systems with the 
neat (unfilled) resin would be tested first.  
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Neat Chemical Cure of SM – GNT  
In oxiranes, the ring opening polymerization process is cationic and involves an 
acid catalyzed protonation of the oxygen.28,39-41  Using this reasoning, a variety of acids 
belonging to the categories of weak, strong, super, and Lewis acids were identified (Table 
2.1) as possible chemical initiator systems.  Initially, SilMix (SM) was combined with 
one of the fourteen acids at a concentration of less than or equal to 20 wt% (Table 2.2).  
The “completeness” of polymerization was evaluated using the GNT.  If the tested 
material did not support the one-lb. needle, it resulted in a failure.  Hexafluorophosphoric 
acid (HFPA) was the only acid of all the acids that were tested, which polymerized to 
hardness (as per the GNT) in less than one h.  For sulfuric and triflic acids, 
polymerization occurred but the resulting materials were too brittle to support the GNT 
and thus failed the polymerization screening.  In the case of acetic acid, no 
polymerization was observed, even with 20 wt% addition of acid and after 48 h post 
addition.  Some reaction/polymerization was observed in the remaining acids at 
concentrations as high as 20 wt%.  Even so, none of them passed the GNT and were not 
considered further.  The summary of these results are listed in Table 2.2.   
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Table 2.1: Types of acid catalysts tested.   
Acids Lewis Acid Weak Acid Strong Acid Super Acid 
Acetic Acid 
 
X 
  Aluminum Chloride X 
   Hexafluorophosphoric Acid 
   
X 
Hydrobromic Acid 
  
X 
 Hydrochloric Acid 
  
X 
 Hydroiodic Acid 
  
X 
 Pentafluoropropionic Acid 
 
X 
  Phosphoric Acid 
 
X 
  Sulfuric Acid 
  
X 
 Tin (IV) Chloride X 
   p-Toluenesulfonic Acid  
 
X 
  Trichloroacetic Acid  
 
X 
  Trifluoroacetic Acid  
 
X 
  Triflic Acid (Trifluoromethanesulfonic) 
   
X 
 
 
 
It is interesting to note that there was only one acid that passed this initial test, 
HFPA.  It is one of two super acids tested and is an excellent proton donor.  The catalytic 
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process involves homopolymerization – another epoxide adds to the protonated epoxy 
group.  There is no competing reaction because the corresponding counterion, PF6-, is 
non-nucleophilic and does not add to the protonated epoxy group as a nucleophile.40  On 
the other hand, HCl is a strong acid and the chloride has the ability to act as a nucleophile 
and add to the protonated epoxide.  The chloride is a smaller, “harder” ion as compared to 
PF6-.  It is why the Cl- is able to compete for the addition to the protonated epoxy group 
and terminates the polymerization.40  Since most of remaining acids were more similar to 
HCl than to HFPA, this reasoning may explain why they did not work.  Unfortunately, 
even though the HFPA system passed, there were drawbacks: short handling time of (less 
than 30 sec) with rapid polymerization to hardness resulting as brittle crystalline material, 
which was an unacceptable initiation system for a silorane-based bone cement (Figure 
2.1).   
 
 
Figure 2.1: Pictures of crystalline samples containing a) 4.6 wt% or b) 2.5 wt% HFPA. 
a)    b) 
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Table 2.2: Summary of polymerization results for initial acids.  
Acids Wt %  GNT Results 
Acetic Acid 5% NR 
Aluminum Chloride 13% NR 
Hexafluorophosphoric Acid 2.5, 4, 4.5, 5% Passed  
Hydrobromic Acid 7.5% NR 
Hydrochloric Acid 2, 5, 10, 14, 18% Failed  – IP 
Hydroiodic Acid 6% NR 
Pentafluoropropionic Acid 4, 15, 18% Failed  – HC 
Phosphoric Acid 7.8% Failed  – IP 
Sulfuric Acid 8% Failed  – Brittle 
Tin (IV) Chloride 7.4% Failed  – IP 
p-Toluenesulfonic Acid  11.5% NR 
Trichloroacetic Acid  9% Failed  – IP 
Trifluoroacetic Acid  7% NR 
Triflic Acid  2, 4% Failed  – Brittle 
NR = No Reaction, IP = Incomplete Polymerization, and HC = Some Polymerization at High 
Concentrations, Bolded samples passed 
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Since there was only one successful monoacid system, HFPA, which had 
significant drawbacks, combinations of acids and other initiation components were 
investigated next.  Inhibitors (normally amines due to their ability to quench acidic 
reactions)54,55 were also included so as to increase the handling time of HFPA.  A total of 
38 acid combinations with and without inhibitors were studied (Table 2.3).  A complete 
list of all formulations and their polymerization results are listed in Appendix B.  Only 
three of the combination systems were promising, acetic acid/HFPA (1.0/3.2 wt%s), 2-
aminopyridine/acetic acid/HFPA (2.7/2.5/8.2 wt%s), and phosphoric acid/PIH (2.2 / 1.6 
wt%s).  The addition of acetic acid to the HFPA resulted in increased handling times and 
polymerized material was more amorphous, taffy-like as compared to samples with 
HFPA alone (Figure 2.2a).  The 2-aminopyridine (2.7 wt%), acetic acid (2.5 wt%), and 
HFPA (8.2 wt%) system produced a smooth material that passed the GNT but in 5 h.  
The last combination of phosphoric acid (2.2 wt%) and PIH (1.6 wt%), passed the GNT 
at 6 h time point. The resulting material was a clear, colorless polymer with some 
intermittent white whiskers (Figure 2.2b).  These three formulations, HFPA, 2-
aminopyridine/acetic acid/HFPA and the phosphoric acid/PIH, underwent pH testing for 
the next phase of screening. 
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Table 2.3: Chemical initiation systems. 
Chemical Initiation Systems 
Acetic Acid (AA) Phosphoric Acid:PIH (phenyl iodonium salt) 
Aluminum Chloride HFPA:Acetic Acid  
Hexafluorophosphoric Acid (HFPA) HFPA:Butylhydroxytoluene 
Hydrobromic Acid HFPA:Pyridine 
Hydrochloric Acid HFPA:12-crown-4 ether 
Hydroiodic Acid HFPA:Pyridine:Acetic Acid 
Pentafluoropropionic Acid HFPA:Triethylamine 
Phosphoric Acid HFPA:Triethylamine:Acetic Acid 
Sulfuric Acid HFPA:Acetonitrile  
Tin (IV) Chloride HFPA:Acetonitrile:Acetic Acid 
p-Toluenesulfonic Acid (p-TSA)  HFPA:p-Nitroaniline  
Trichloroacetic Acid  HFPA:2,6-dinitroaniline 
Trifluoroacetic Acid  HFPA:Sulfanilamide  
Triflic Acid (Trifluoromethanesulfonic) HFPA:Phenylenediamine  
Triflic Acid:Acetic Acid HFPA:2-aminopyridine (2AP) 
p-TSA:pentafluoropropionic acid  HFPA:Ethanol  
Phosphoric Acid:Ethanol HFPA:Ethanol:Acetic Acid 
2-aminopyridine:Potasium-tert-butoxide HFPA:2-aminopyridine:Acetic Acid 
Bolded samples passed 
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Figure 2.2  Pictures of a) HFPA with acetic acid  and b) Phosphoric acid with PIH. 
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Neat Chemical Cure of SM – pH Testing 
Since acids were used in the initiation system, it was necessary to determine the 
pH of the polymerized material as a pre-screening for biocompatibility. If all of the acid 
from the initiation system was not completely consumed or if there was an acidic by-
product produced during the polymerization, the resulting polymer would be acidic, 
which may cause cell death or necrosis. For bone cells, such as osteoblasts, the optimal 
environmental pH is 7.4.  When the environment becomes more acidic, cell death 
occurs.43  Even a decrease as small as 0.4 units can result in a 40% decrease in cell 
viability.43  Due to this issue, a test involving pH was developed.  Light-cured SilMix 
(LCSM) was used as the control since it was previously determined as biocompatible 59,66 
and must have acceptable pH properties.  For samples to move forward onto 
biocompatibility testing, the change in pH must be within 0.5 units of the pH change 
produced by the control. 
For this study, samples were placed in beakers with deionized or distilled water, 
and the pH was measured over one h at 15 min increments.  The change in pH was 
determined by taking the difference of the initial pH of the water without the sample and 
the final pH after one h.  The control (LCSM) was compared to HPFA (5.0 wt%), 2-
aminopyridine/acetic acid/HFPA (2.7/2.5/8.2 wt%s), and phosphoric acid/PIH (2.2/1.6 
wt%s) samples.  The control resulted in a 1.11 unit decrease in one h.  The sample with 
the largest change after one h, a 3.55 unit decrease, was the phosphoric acid/PIH (2.2/1.6 
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wt%s), which also had the longest polymerization time (6 h).  The HPFA sample (5.0 
wt%) was the next largest, for which in one h the pH decreased by 2.81 units.   The 2-
aminopyridine/acetic acid/HFPA (2.7/2.5/8.2 wt%s) formulation resulted in a total pH 
decrease of 1.45 units in one h (Table 2.4), which was within 0.5 units of the control.   
 
 
Table 2.4: pH change after one h for chemically cured SilMix. 
Sample $pH  
Light-cure (control) -1.11 
HFPA (5.0 wt%) -2.81 
H3PO4 (2.2 wt%)/PIH(1.6 wt%) -3.55 
2-AP(2.7 wt%)/AA(2.5 wt%)/HFPA(8.2wt%) -1.43 
 
 
Due to the large change in pH and long polymerization time, the phosphoric 
acid/PIH system was not considered viable moving forward.  The 5 wt% HFPA 
formulation was also not considered for biocompatibility testing, but exothermicity of the 
polymerization was tested.  The 2-aminopyridine/acetic acid/HFPA (2.7/2.5/8.2 wt%s) 
formulation passed the pH test and was screened for biocompatibility.  
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Neat Chemical Cure of SM – Exothermicity 
As mentioned in the previous chapter, heat generated during the polymerization of 
PMMA-based bone cement can cause necrosis of surrounding tissue and cells.2,12,42  A 
desirable material was required to produce the same, if not less, heat upon polymerization 
than commercial bone cement.  For the exothermicity testing of the HFPA system (5 
wt%), commercially available bone cement (Stryker Simplex® P) was used as the control.  
Both the rate of polymerization and maximum exotherm were found to be significantly 
different between the control and HFPA system (5 wt%).  For the commercial material, a 
peak exotherm of 62.4 °C was observed approximately 14 min post-initiation and then 
remained above 45 °C for approximately one min.  In contrast, the HFPA initiated 
sample had a maximum exotherm of 36.1 °C after one min post initiation (Figure 2.3) 
and was statistically different than the maximum exotherm of commercially available 
bone cement (Table 2.5).  Therefore, HFPA passed the exothermicity screening.   
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Figure 2.3: HFPA vs. Simplex P exotherms. 
 
 
 
 
Table 2.5: Exothermicity comparisons for testing initiation systems and control. 
Material Maximum Exotherm Time of Peak Exotherm  
Simplex P 62.4 °C 14 min 
HFPA (5 wt%) 36.1 °C 1 min 
LCSM  127.2 °C Immediately after irradiation 
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Neat Chemical Cure of SM – Biocompatibility 
Biocompatibility was tested using MLO-A5 cells with the Trypan Blue (TB) 
Exclusion and MTT assays. Cell death was measured using the TB assay while the MTT 
assay indicated cell viability, both of which were defined in Chapter 1.  For these studies, 
all samples were compared to two controls; empty cell wells and light-cured SilMix 
(LCSM) samples.  The biocompatibility of the chemical initiation system that passed the 
pH screening (2-aminopyridine (2.7 wt%), acetic acid (2.5 wt%), and HFPA (8.2 wt%)) 
was tested.  Samples (n=4) were prepared in our laboratory and given to our collaborator, 
Dr. Nalvarte, at the UMKC School of Dentistry for biocompatibility testing.  In addition 
to the TB and MTT assays of the cells in direct contact with the material, the MTT assay 
of cells in contact with media, which was exposed to polymer samples and contained 
potential leachable extracts, was also studied.   
There was no significant difference between the live/dead cell percentages of 
LCSM and the empty control wells (p>0.05), which was consistent with previous 
data.59,66  On the other hand, the SilMix (86.6 wt%), 2-aminopyridine (2.7 wt%), acetic 
acid (2.5 wt%), and HFPA (8.2 wt%) system resulted in 100% cell death. It was observed 
as a color change in cells from colorless to blue and a change in the media from blue to 
yellow, which were attributed to the change in pH observed during that screening test 
(Figure 2.4 a-b).  This result was attributed to residual HFPA, which was not consumed 
during the initiation reaction.  In summary, the HFPA chemically cured samples were not 
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biocompatible so this initiation system was not appropriate as a possible initiation system 
for the silorane bone cement. 
   
 
Figure 2.4: Biocompatibility of chemical-cure SilMix (HFPA) vs. light-cure SilMix 
(LCSM) a)Trypan Blue and b) MTT of leachables. 
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Neat Chemical Cure of SM – Summary 
A chemical cure system was identified that would polymerize the neat SilMix 
with a low exotherm.  However, it was toxic and had poor handling times.  Due to these 
issues, a new approach toward the initiation system was needed.  Investigations began 
into a dual or mixed initiation system.  A “dual” cure system was defined as containing at 
least one acid and a photosensitizer, which required some type of light source for 
initiation. 
 
! 85 
Mixed Initiation of SM – GNT 
In an attempt to identify an appropriate initiation system for the silorane material, 
which did not suffer from any of the previously determined drawbacks, dual cure or 
mixed initiated systems were also investigated.  The mixed initiation systems contained a 
photosensitizer and at least one acid.  They also required direct irradiation with a light 
source for initiation.  As with the chemical initiators, the mixed systems also needed 
screening tests.  As with the previous studies of the chemical systems, the GNT, pH test, 
degree of conversion, and finally biocompatibility were used for this purpose. 
For the GNT test, ten combinations were investigated (Table 2.6) and only two 
systems showed promise.  The first was a combination of SilMix (94.0 wt%), phosphoric 
acid (2.0 wt%), PIH (3.0 wt%), and camphorquinone (CPQ, 1.0 wt%).  The sample 
polymerized to hardness after five min of irradiation with a 100-watt halogen light bulb 
(~ 40 cm away).  The setup was designed using inexpensive, common materials and is 
depicted in Figure 2.5.  In the second system, the phosphoric acid was replaced with 
acetic acid to give a less acidic option.  This formulation contained SilMix (93.0 wt%), 
acetic acid (3.0 wt%), PIH (3.0 wt%), and CPQ (1.0 wt%).  After five min of irradiation 
with the halogen light source, the sample polymerized to hardness and resulted in a clear, 
light yellow polymer (Figure 2.6).  Of the eleven combinations tested, only the 
phosphoric acid/PIH/CPQ and acetic acid/PIH/CPQ systems were moved forward to the 
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pH screening test.  A complete list of the system concentrations investigated and their 
polymerization results are given in Appendix B. 
 
 
 
Table 2.6: Mixed initiated systems.     
Mixed Initiation Systems 
Acetic Acid:PIH 
HFPA:Phosphoric Acid:PIH 
Phosphoric Acid:Trifluoroacetic Acid:PIH 
Phosphoric Acid:Trichloroactic Acid:PIH  
Phosphoric Acid:Triflic Acid:PIH 
Phosphoric Acid:p-TSA:PIH 
Tin (IV) Chloride:PIH 
Tin (IV) Chloride:Phosphoric Acid:PIH 
Phosphoric Acid:Camphorquinone:PIH 
Acetic Acid:Camphorquinone:PIH  
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Figure 2.5: Halogen lamp set up.   
 
 
 
 
Figure 2.6: SilMix, acetic acid, PIH, and CPQ system.   
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Mixed Initiation of SM – pH Testing 
The mixed initiation systems that passed the GNT underwent pH screening.  As 
was found in the chemical cure investigation, the pH of the material can have an effect on 
cytotoxicity.  The pH test criteria was limited to a pH change within -0.2 to +0.3 units of 
the control.  Those tested formulations were the phosphoric acid/PIH/CPQ (2.0/3.0/1.0 
wt%s) and the acetic acid/CPQ/PIH (3.0/3.0/1.0 wt%s) and compared to three of the 
chemical systems and LCSM as the control.  Unfortunately, the pH change for the 
phosphoric acid system was quite large (2.30 unit decrease after one h) as compared to 
the control.  On the other hand, the pH change of acetic acid system after one h yielded a 
decrease of 0.81 units, which was less than the control (Table 2.7).  Because of these 
results, only the acetic acid formulation moved on to the additional screening tests, 
degree of cure and biocompatibility. 
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Table 2.7: Change in pH for different initiation systems after one h. 
Sample $pH  
Light-cure (control) -1.11 
HFPA (5.0 wt%) -2.81 
H3PO4 (2.2 wt%)/PIH(1.6 wt%) -3.55 
2-AP(2.7 wt%)/AA(2.5 wt%)/HFPA(8.2wt%) -1.43 
H3PO4 (2.0 wt%)/PIH(3.0 wt%)/CPQ(1.0 wt%) -2.30 
CH3COOH (3.0 wt%)/PIH(3.0 wt%)/CPQ(1.0 wt%) -0.81 
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Neat Mixed Initiation of SM – Degree of conversion (DC) 
There was only one mixed system that had passed the GNT and pH screening 
tests, the acetic acid formulation (acetic acid (3.0 wt%)/PIH(3.0 wt%)/CPQ(1.0 wt%)).  
This study was conducted with Dr. Melander at the UMKC School of Dentistry.  Fourier 
Transform Infrared Spectroscopy (FTIR) was used to determine the degree of conversion 
of SilMix samples by comparing the change in the peak associated with silorane 
polymerization (883 cm-1 representing the oxirane ring opening) to an internal standard 
peak (1257 cm-1 representing the Si-O bond in the CYGEP ring).  The peak ratios were 
then calculated.   
The summary of the DC for the acetic acid system and LCSM are found in 
Figures 2.7a and 2.7b.  The DC of the acetic acid system was initially lower than that of 
the LCSM after 60 min. After one min, the LCSM reached 41% DC; while after 60 min, 
the mixed system had only achieved 24% DC.  However, after 20 h, the mixed system 
(69%) increased to that of the LCSM (72%).  The rate of polymerization of the mixed 
system was slower, but continued to increase over a longer period of time compared to 
the LCSM, even when kept in the dark (dark cure).  This result allowed the system to 
move on to biocompatibility testing. 
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Figure 7: DC of LC and MI SilMix a) from 0 to 60 min and b) after 20 h. 
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Neat Mixed Initiation of SM – Biocompatibility 
The mixed system consisting of SilMix (93.0 wt%), acetic acid (3.0 wt%), PIH 
(3.0 wt%), and CPQ (1.0 wt%) was tested for biocompatibility using LCSM and an 
empty cell culture well as controls in the Trypan blue assay. It was the only system to 
pass all the previous screening tests; GNT, pH, and DC.  Samples (n=6) were prepared in 
our laboratory and given to collaborators at the UMKC School of Dentistry for testing.  
The MLO-A5 cells cultured with the mixed initiated (MI) system were comparable to the 
LCSM at 24 and 48 h (Figure 2.8).  As with the previous tests, the live cell numbers from 
both the SilMix samples, at both 24 and 48 h, were lower than the empty wells, but the 
dead cells numbers for all samples were similar (Figure 2.8 a-b).  The percent live/dead 
cells were comparable for all at both time points (Figure 2.8 c-d).  Because of these 
results, the acetic acid system was found to be biocompatible and thus a viable option for 
a mixed initiated bone cement. 
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Figure 2.8: Number of live/dead cells at a) 24 h, b) at 48 h, and percent live/dead cells at 
c) 24 h, and d) at 48 h. 
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Filled Mixed Initiated SM – Filler Screening  
Composites are filled materials and are essentially resins filled with glass or other 
filler particles.  From previous work mentioned in Chapter 1, three fillers and three 
modifications were identified for use in this bone cement.  They were DY5, M12, and 
alumina nanofibers (ANF).  The DY5 and M12 glasses (Table 2.8) were manufactured by 
collaborators at MoSci Co (Rolla, MO), and the nanofibers were generated by another 
collaborator, Dr. Thomas Schuman from Missouri University of Science and Technology 
(Rolla, MO).  Dr. Schuman also surface treated all three fillers with modifications 
synthesized in his laboratory.  Of the three modifications identified previously, only one 
was used for this test, 2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane (ECHE, 45) (Figure 
2.9).   
 
 
 
Table 2.8: Filler compositions (in wt%). 
Filler BaO Ba2O3 Y2O3 Al2O3 SiO2 
DY5 0 0 15% 5% 80% 
M12 29.1% 10.5% 0 5.9% 54.5% 
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Figure 2.9: Structure of ECHE monomer used for filler modification. 
 
 
 
At this point, the best neat mixed system was the acetic acid (AA) system 
AA:PIH:CPQ (3:3:1 wt%s), which was irradiated for five min with a 100-watt light bulb 
(~ 40 cm away). The three fillers were added to this system in amounts ranging from 10 – 
50 wt%, and the polymerization of the resulting material was tested using the GNT.  A 
sample passed if no mark nor indentation resulted from the placement of the one-lb. 
needle (Table 2.9). 
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Table 2.9: Summary of mixed initiation filler screening. 
Filler Type Filler Surface Modification % Filled (by wt) Pass/Fail 
DY5 None 10% Pass 
DY5 None 20% Pass 
DY5 None 30% Pass 
M12 None 50% Pass 
ANF  None 10% Pass 
ANF  None 20% Pass 
ANF  None 30% Fail 
ANF  None 50% Fail 
ANF  ECHE 10% Pass 
ANF ECHE 20% Pass 
ANF ECHE 30% Pass 
ANF ECHE 50% Pass 
 
 
 
For DY5, all tested samples (10, 20, and 30 wt%s) passed the GNT.  M12 glass 
passed at 50 wt% filled but the disc was slightly wet on top.  Unmodified ANF passed at 
smaller amounts (10 and 20 wts%), but failed at the higher amounts (30 and 50 wt%s). 
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However, the ECHE-surface modified ANF passed at all tested amounts (10, 20, 30, and 
50 wt%).  A picture of a mixed initiated sample filled with ECHE-modified ANF is 
depicted in Figure 2.10.  From these results, the DY5, M12, and ECHE-modified ANF 
passed the polymerization screening and were used for future testing.  Next, the 
optimization of the system was investigated, which included changes in the formulations 
and alternative light sources. 
 
 
 
Figure 2.10: Sample of mixed initiated SilMix. 
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Filled Mixed Initiated SM – Acetic Acid and Temperature Changes 
After the fillers were identified, the effect of irradiation time was investigated by 
increasing the acid component of the initiation system or the temperature during 
irradiation.  It was proposed that the rate of polymerization would increase with an 
increase in the amount of acetic acid (AA).  The tested range was increased from 3 wt% 
to 6 wt%.  No advantage was observed in the filled material (DY5 or modified alumina 
nanofibers) when the wt% of AA was increased.  In addition, there was no change in the 
polymerization time with the addition of more AA.  The samples still required irradiation 
for the full five min.  Next, the effect of heat on a filled mixed system was tested with 
DY5 (50 wt%).  The sample was placed on a hot plate (approximately 35 °C) instead of 
the bench top (approximately 22 °C) during irradiation.  The additional heat did not 
improve polymerization time.  With or without heat, samples filled with DY5 (50 wt%) 
polymerized at five min under the lamp.   Because of these test results, it was determined 
that the amount of AA (3 wt%) and the heat should remain unchanged. 
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Filled Mixed Initiated SM – Type of Light Source 
The type of light source used to irradiate the filled mixed system AA:PIH:CPQ 
(3:3:1 wt%s) was investigated.  The new light sources were selected by their availability 
and size, which would eliminate the need to buy large or specialized lights to utilize this 
bone cement.  A typical penlight, flashlight, and 60-watt halogen light bulb were used for 
this experiment.  The more portable light sources, such as a flashlight and a penlight, 
were investigated first.  Five mixed initiation samples, which were filled to 50 wt% with 
ECHE-modified alumina nanofibers (ANF), were irradiated at one, two, three, four, and 
five min with a penlight.  No change or polymerization was observed in any of the 
samples.  Next, five filled mixed initiated samples containing 50 wt% ECHE modified 
ANF were irradiated from one to five min with a flashlight (Figure 2.11).  The sample 
that was irradiated for five min with a flashlight (~ 4 cm away) showed some hardening 
but did not completely polymerize.  It barely passed using the # lb. GNT.  In order for it 
to pass the one lb. GNT, the sample required an irradiation time of 8 min.  For the next 
samples, the effect of filler on the rate of the polymerization was carried out by changing 
the filler to 25 wt% ECHE-modified ANF and 25 wt% DY5.  After 10 min of irradiation 
with the flashlight, the samples polymerized slower than the ECHE-modified ANF alone 
at 50 wt%. 
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Figure 2.11: Depiction of flashlight set up. 
 
 
 
 
After the disappointing results with the two portable options, the intensity of the 
light bulb was changed to 60-watts from the original 100-watts.   For samples irradiated 
with the 60-watt bulb, it took over four times as long (25 min) and at a shorter distance 
(20 cm) to polymerize the sample.  For the 100-watt bulb, it only took five min at 40 cm 
way.  The temperature of the 60-watt light bulb after five min was 77 °C compared to 
100 °C with the 100-watt bulb.  The cooler temperatures and lower intensity of the 60-
watt light source slowed the polymerization of these samples.  In summary so far, these 
portable options are not viable because there was either no or extremely slow 
polymerization of the samples (Table 2.10). 
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Table 2.10: Summary of light source trials. 
Filler Type and Amount (wt%) Light Source Irradiation Time Pass/Fail 
ECHE mod ANF 50% Pen Light 1 min Fail 
ECHE mod ANF 50% Pen Light 2 min Fail 
ECHE mod ANF 50% Pen Light 3 min Fail 
ECHE mod ANF 50% Pen Light 4 min Fail 
ECHE mod ANF 50% Pen Light 5 min Fail 
ECHE mod ANF 50% Flashlight 1 min Fail 
ECHE mod ANF 50% Flashlight 2 min Fail 
ECHE mod ANF 50% Flashlight 3 min Fail 
ECHE mod ANF 50% Flashlight 4 min Fail 
ECHE mod ANF 50% Flashlight 5 min Fail 
ECHE mod ANF 50% Flashlight 8 min Pass 
ECHE mod ANF 25% & DY5 25% Flashlight 10 min Pass 
ECHE mod ANF 50% 60-watt light bulb 25 min Pass 
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Summary of Mixed Initiated SM 
A biocompatible initiation system that resulted in good handling times, which 
polymerized a filled formulation in desirable time frame, was identified.  However, the 
samples required direct irradiation with an external light source.  Even though the light 
sources were small, inexpensive, and readily available, they are still inconvenient for use 
with a bone cement.  Another, purely chemical, initiation system was required for this 
project to move forward. 
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Neat Redox Cure of SM – GNT 
With drawbacks of the toxicity of the HFPA option and the requirement of 
irradiation by a light source for mixed initiated system (AA:PIH:CPQ (3:3:1 wt%s)), 
there was a need for a paradigm shift for the approach of the initiation system.  Therefore, 
the possibility of organometallic catalyst alternatives was investigated.  Redox chemical 
initiators are a newer class of cationic initiators that were initially used for synthetic 
reactions.44-48  There were several considered for the bone cement use, including Pt (e.g., 
Karstedt and Lamoreaux catalysts), Pd (e.g., Lindlar catalyst), and Rh (e.g., Wilkinson’s 
catalyst) –based catalysts.  Lamoreaux catalyst (LMC) was readily available and came to 
mind because of it is use as the catalyst in the preparation of the CYGEP monomer.62  
Molleo and Crivello50 found that a combination of an onium salt, an 
organometallic catalyst, and a silane would polymerize oxirane monomers.  For the 
polymerization of cyclohexene oxide (48), they used 1,1,3,3-tetramethyldisiloxane 
(TMDS, 49) as the reducing agent, S-methyl-S-n-hexadecyl-S-phenacylsulfonium 
hexafluoroantimonate (DPS, 50) as the oxidizing agent, and Pt-based Karstedt catalyst 
(Figure 2.12 a-c).  They proposed that the addition of catalyst generates a hydride anion 
from the silane on TMDS.  This hydride anion then fragments the DPS, yielding a dialkyl 
sulfide, an aryl methyl ketone, and a proposed species with “silicenium ion-like”50 
characteristics.  This species would then react with any trace amounts of water to give a 
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strong/super Brønsted acid, which then initiates the polymerization of cyclohexene 
oxide.50  
 
 
 
Figure 2.12: Structures of cyclohexene oxide (48), TMDS (49) and DPS (50). 
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methylphenylsilane), but it was found that special care in mixing was needed because the 
heat generated caused the material to polymerize to hardness in the mixer.  As a result, a 
mixing protocol was established.  First, SilMix and PIH were combined in the mixer, and 
then the LMC was added and mixed in by hand for 30 sec so as to slow the 
polymerization reaction.  The resulting sample was a clear, light brown material that had 
a handling time of approximately five min before it began to gel.  It polymerized to 
hardness (GNT) between 15 – 30 min depending on the mass of the material.  The thicker 
samples polymerized in 15 min; while the thinner ones took longer (30 min).  For these 
tests, the formulation was 99.89 wt% SilMix, 0.07 wt% LMC, and 0.04 wt% PIH.  It was 
a substantial improvement over the previous systems, which resulted in fast 
polymerization times with very short handling periods or very slow polymerization times 
with long working periods.  Next, the LMC/PIH system was required to pass the pH and 
exotherm screenings before it could be tested for biocompatibility. 
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Neat Redox Cure of SM – pH Testing 
For this study, the acidity of a material was measured by the change in pH of 
deionized or distilled water containing a polymer.  As mentioned previously, cell death 
occurred when the environmental pH became acidic,43 which was observed in the 
biocompatibility of the 2-aminopyridine/acetic acid/HFPA initiated material.  For a 
sample to pass the pH test, the pH change must be within -0.2 - +0.3 units of the control.  
LMC/PIH (0.07/0.04 wt%s) was compared to the control, LCSM, as well as previous 
chemical cure systems, HPFA (5.0 wt%), phosphoric acid/PIH (2.2/1.6 wt%s), and 2-
aminopyridine/acetic acid/HFPA (2.7/2.5/8.2 wt%s).  The LMC/PIH (0.07/0.04 wt%s) 
formulation yielded the smallest decrease in pH of 0.98 units in one h and was the closest 
to the control (Table 2.11).  Due to the small change in pH, the LMC/PIH (0.07/0.04 
wt%s) system underwent exothermicity and biocompatibility testing.   
 
 
 
 
 
 
 
 
! 107 
Table 2.11: pH change after one h for chemically cured SilMix. 
Sample $pH  
Light-cure (control) -1.11 
HFPA (5.0 wt%) -2.81 
H3PO4 (2.2 wt%)/PIH(1.6 wt%) -3.55 
2-AP(2.7 wt%)/AA(2.5 wt%)/HFPA(8.2wt%) -1.43 
LMC (0.07 wt%)/PIH(0.04 wt%) -0.98 
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Neat Redox Cure of SM – Exotherm 
The ideal material would have a maximum exotherm lower than that of 
commercial bone cement, specifically 45 °C or below.  For this test, the LMC/PIH-
initiated SilMix (SilMix 99.89 wt%, LMC 0.07 wt%, and PIH 0.04 wt%) was compared 
to LCSM (rate and maximum exotherm of polymerization) and a commercial bone 
cement, Simplex P (maximum exotherm of polymerization).  With respect to LCSM, 
there was a difference in both the rate of polymerization and maximum exotherm.  For 
the LCSM, a peak exotherm of 127.2 °C was achieved immediately after light initiation 
and remained above 45 °C for approximately one more min.  In comparison, the 
LMC/PIH initiated SilMix reached the maximum exotherm of 34.1 °C at 1-2 min post 
initiation (Figure 2.13).  Simplex P had a maximum exotherm of 62.4 °C.  Therefore, the 
LMC-initiated system resulted in a statistically (p<0.05) lower maximum exotherm than 
bone cement and LCSM (Table 2.12).  With an exotherm below the 45 °C threshold, the 
LMC/PIH system was continued onto biocompatibility testing.   
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Figure 2.13: LMC/PIH vs. LCSM exotherms. 
 
 
 
 
Table 2.12: Exothermicity comparison. 
Material Maximum Exotherm Time of Peak Exotherm  
Simplex P 62.4 °C 14 min 
LCSM  127.2 °C Immediately after irradiation 
LMC/PIH (0.07 wt%/0.04 wt%) 34.1 °C 1.5 min 
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Neat Redox Cure of SM – Biocompatibility 
Biocompatibility was tested with MLO-A5 cells using the Trypan Blue (TB) 
Exclusion and MTT assays for cell death and cell viability, respectively. As with all of 
previous studies, the LMC/PIH initiated silorane, comprised of SilMix (99.89 wt%), 
LMC (0.07 wt%), and PIH (0.04 wt%), was compared to two controls: empty cell wells 
and light-cured SilMix (LCSM).  Samples (n=6) were prepared in our laboratory and 
given to Dr. Bi, a collaborator at the UMKC School of Dentistry, for testing.  According 
to the Trypan blue assay, the number of live cells for the LCSM and the LMC/PIH were 
significantly less (p<0.05) than the empty control wells, however, there was no 
significant difference in the dead cell count (Figure 2.14).  When comparing the live/dead 
percentages, the LCSM, LMC/PIH, and control wells were the same (Figure 2.15), which 
indicated that the reduction in the cell number in the SilMix samples was the result of 
reduced proliferation and not toxicity.  This reduced proliferation was likely the result of 
poor cell adherence to the smooth polymer surface.  This phenomenon had been seen 
with previous SilMix samples.59  The MTT assay confirmed the biocompatibility of the 
SilMix samples (Figure 2.16).  In the presence of extracts from LCSM (OD=0.95±4) and 
LMC/PIH (0.96±3), the Formazan products were similar to the controls (0.92±5).  With 
these results, the LMC/PIH biocompatibility studies showed that this particular 
formulation was comparable to the LCSM and thus a viable initiation system for use in a 
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bone cement.  One last test was undertaken to complete the screening process, degree of 
conversion. 
 
 
 
Figure 2.14: Cell count of live and dead adherent and non-adherent cells after 24 and 48 h 
incubation with MLO-A5 cells.  
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Figure 2.15: Percentage of live and dead cells in the 24 and 48 h cultures. 
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Figure 2.16: MTT formazan product formation: Extracts from 24h incubation of 
polymers in media with serum. !
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Neat Redox Cure of SM – Degree of Conversion (DC) 
After the LMC/PIH initiation system (LMC (0.07 wt%)/PIH(0.04 wt%)) passed 
the GNT, pH, exotherm, and biocompatibility testing, it underwent DC testing as 
compared to LCSM.  This study was conducted with Dr. Melander at the UMKC School 
of Dentistry.  Due to the inability to achieve an appropriate baseline for the LMC, the 
results were analyzed using the LCSM baseline to calculate the degree of conversion.  It 
was found that the LMC system had a lower degree of cure (~30%) as compared to the 
LCSM (~70%) 18 h post-initiation (Figure 2.17).  With this test, it appeared as though the 
LCSM cured more than the LMC system.  However, due to the issue with the baseline, 
no definitive conclusion could be made. 
 
 
Figure 2.17: Degree of conversion of LCSM and LMC after 18 h. 
0.0% 
10.0% 
20.0% 
30.0% 
40.0% 
50.0% 
60.0% 
70.0% 
80.0% 
~18 hrs 
D
eg
re
e 
of
 C
on
ve
rs
io
n light cured 
"chemical 
cure (LMC)" 
! ''+!
Summary 
Throughout this work, numerous initiation systems were investigated, but only a 
few indicated any promise with respect of the parameters required for a bone cement.  
The mixed system (AA:PIH:CPQ (3:3:1 wt%s) filled to 50 wt% with DY5 and ECHE 
modified ANF (1:1 by wt) is a possible option for a bone stabilizer with the drawback of 
the requirement of light initiation.  Since one of the main goals for this research was to 
determine an option whereby direct irradiation with an external light source was not 
required, the LMC/PIH system consisting of 0.07 wt% LMC and 0.04 wt% of PIH was 
the best choice with respect of a chemical cure.  This formulation had a good handling 
time (approximately five min) and complete polymerization to hardness in an acceptable 
timeframe (30 min).  The resulting formulation was also biocompatible, which is another 
key requirement for internal use.  The development of a bone cement using the LMC/PIH 
initiation system is discussed in the next chapter. !
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CHAPTER 3 
 
SILORANE-BASED BONE CEMENT  
 
 
 
Introduction 
As discussed in the previous chapters, a viable alternative formulation for a novel 
silorane bone cement was developed.  A neat chemical cure system was identified, as 
well as, a filled mixed initiated option.  The mechanical and handling properties for the 
formulations were tunable depending on the desired applications.  While the 
biocompatibility and handling times for both systems were acceptable, there were still 
some drawbacks for each of the options.  The chemical cure system was successful but 
only for the neat silorane resin, however for a composite alternative, filler was required.  
The filler in the mixed initiated material gave it strength, but it still required some light 
irradiation for polymerization.  This requirement of an external light source limited its 
use internally and thus not appropriate for a bone cement application.  Due to these 
problems with both alternatives discussed Chapter 2, a new formulation was required and 
possibly an alternative initiation system. 
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As a reference, the standard for “Implants for surgery – Acrylic resin cements,” ISO 5883 
was used to refine and define the viable formulations.57  Using this standard, emphasis 
was placed on exothermicity, handling time, flexural strength, and flexural modulus 
(Table 3.1).  Biocompatibility and pull out strength were also investigated for 
thoroughness.  The goal was to identify a material that would be used in live animals, 
first small (rats), then large (swine). 
 
Table 3.1: Desired properties of bone cement. 
  ISO 5833 Standard
57 Desired properties 
Exothermicity (°C) !90 !45 
Handling time (min) 3-15 !20 
Flexural modulus (GPa) "1.8 "1.8 
Flexural strength (MPa) "50 "50 
Compressive strength (MPa) "70 "70 
Pull out strength – mimic (MPa) n/a "4.5 
Pull out strength – ex vivo (MPa) n/a "4.5 
Pull out strength – in vivo (MPa) n/a "4.5 
Cytotoxicity (% cell death) n/a !20% 
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Prototype 1 (P1) – GNT 
After identifying possible initiation systems for SilMix, the next goal was to 
develop a new bone cement formulation.  Currently available bone cements are packaged 
as two components, a liquid and a powder, both containing methacrylates.  Therefore, 
using this model as a guideline, the initial investigated formulation was comprised of two 
components.  The liquid component was the SilMix comonomer system.  For the 
powdered portion, we used light-cured SilMix (95.85 wt% SilMix (41/42), 3 wt% PIH 
(30), 1 wt% CPQ (25), and 0.15 wt% EDMAB (27)), which was crushed into a powder 
(CSM).  The previously identified LMC/PIH system was utilized as the initiation system.  
The formulations of prototype 1 (P1) were first mimicked after the composition of 
Simplex P (Table 3.2).  The formulation screening was similar to the screening of the 
initiation systems starting with the Gillmore Needle Test (GNT) to test polymerization 
time.  After a formulation passed the GNT, the exothermicity, mechanical, and possibly 
degree of cure testing were investigated. 
 
 
 
 
 
 
 119 
Table 3.2: PMMA Bone cement components vs. P1 components. 
 
PMMA FUNCTION P1- Silorane Based Material 
Methyl methacrylate (1, 
32.3-33%) 
RESIN SilMix (41/42, 35-55%) 
Pre-polymerized PMMA 
beads (2, 55.3-66%) 
FILLER Pre-polymerized SilMix (36-56%) 
Barium sulfate/zirconium 
dioxide (6-10%) 
RADIOPACIFIER Yttrium silicate glass (DY5) (9-14%) 
N,N-dimethyl-p-toluidine 
(DMPT) (3, 0.13-0.93%) 
ACCELERATOR PIH (p-(octyloxyphenyl) 
phenyliodonium 
hexafluoroantimonate) (30, 0.04-
0.27%) 
Benzoyl peroxide (4, 0.5-
1.73%) 
INITIATOR Lamoreaux’s catalyst (0.10-0.30%) 
   
Hydroquinone (5, 5-25 
ppm) 
INHIBITOR Not needed 
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As stated previously, the P1 formulations mimicked the PMMA bone cement 
components and its ratios.  Initially, the crushed SilMix (CSM) was solely light-cured 
SilMix that was crushed using a coffee grinder and then a mortal and pestle.  The first six 
formulations provided a good starting point (Table 3.3).  Changes to the formulations 
including the LMC/PIH ratio were tested.  However, formulation 6 yielded the best 
handling and polymerization times.  The one drawback was the sandy texture.  In terms 
of the eventual use of the material in the body, the graininess could cause irritation and 
inflammation so was not a possible alternative.   
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Table 3.3: Initial formulations for P1. 
 
Sample %SM %PIH %LMC %CSM %DY5 Consistency GNT Pass 
P1-1 34.35 0.04 0.11 55.87 9.62 
damp sand that did not pack 
together well, rough on top 
45min 
P1-2 34.31 0.04 0.27 55.78 9.60 
damp sand that did not pack 
together well, rough on top 
over 6 h 
P1-3 34.34 0.04 0.12 55.88 9.62 
wet sand, packed well, top 
smoothed out  
1 h top wet  
P1-4 34.33 0.04 0.11 55.89 9.62 
wet sand, packed well, top 
smoothed out (placed on hotplate) 
Some parts at 
2.5h  
P1-5 34.34 0.10 0.11 55.83 9.62 
wet sand, packed well, top 
smoothed out 
3.25 h 
P1-6 34.24 0.15 0.15 55.84 9.61 
wet sand, packed well, top 
smoothed out  
15 min 
 
 
 
In order to address this issue, it was decided that the SilMix (CSM) would be milled by 
Dr. Schuman at MS&T so as to obtain a finer, more consistent powder.  The resulting 
CSM was more like the other glass fillers, smooth and fluffy.  There were two different 
sizes +120 and -120, which were produced as the same time and separated with a 120-
sieve.  The finer particles passed through the 120-sieve leaving behind larger material 
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(+120).  The first formulations contained the new milled CSM (+120), and their 
compositions were approximately that of the P1-6 formulation.  Unfortunately, it was 
hard to incorporate all of the new CSM.  The resulting material was too thick and took 
longer to polymerize (over 1 h).  Therefore, the formulation was adjusted to obtain 
polymerization results similar to those of P1-6 (Table 3.4).  This result was accomplished 
by decreasing the amount of the +120 CSM and increasing the DY5, along with toggling 
the LMC/PIH amounts. 
 
 
Table 3.4: Prototype 1 with milled crushed SilMix (+120 size). 
 
Sample %SM %PIH %LMC %CSM %DY5 Consistency GNT Pass 
P1-m1 34.23 0.15 0.21 55.81 9.60 v. dry, v.hard to mix, dry clay 1.25 h 
P1-m2 49.67 0.24 0.30 35.84 13.95 easier to mix, thick paste 30 min 
P1-m3 41.91 0.20 0.27 45.84 11.77 hard to mix, v. thick paste, wet clay 15 min 
 
 
From this study, it was determined that P1-m3 had the most potential due to its 
good consistency and appropriate handling times.  An additional study was used to 
optimized the amount of LMC.  It was found that 0.27 wt% LMC was found to be 
optimal.  The effect of size of the CSM filler was also tested using smaller sized CSM (-
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120) and the P1-m3 formulation.  It was determined that the resulting material had a 
thinner consistency and polymerized faster.  These studies are summarized in Table 3.5. 
 
 
Table 3.5: Prototype 1 with milled crushed SilMix (-120 size). 
 
Sample %SM %PIH %LMC %CSM %DY5 Consistency GNT Pass 
P1-m3b 41.91 0.20 0.27 45.84 11.77 thick paste 3 min 
P1-m4 52.05 0.17 0.17 35.58 11.77 became firmer as mixed 5 min 
P1-m5 49.80 0.17 0.17 35.58 14.00 thick paste 15 min 
P1-m6 42.18 0.10 0.10 45.58 11.77 thick paste 30 min 
P1-m7 49.95 0.10 0.10 35.85 14.00 thick paste 30 min 
 
 
Four formulations passed the GNT screening test and were subjected to further 
investigation.  The original crushed SilMix formulations, P1-5 and P1-6, along with 
milled P1-m7, underwent exothermicity testing.  The mechanical properties of P1-m6 and 
P1-m7 and degree of conversion for P1-m7 were determined. 
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P1 – Exotherm Testing  
For the polymerization exotherm, the desired max temperatures was ideally less 
than 45 °C, which was below the recorded commercial bone cement exotherms 
(approximately 64 °C) and the ISO standard 5833 of 90 °C.  The peak exotherm and the 
setting times were obtained from this test.  The peak exotherm is the highest temperature 
the sample reaches during polymerization and the highest point on the graph.  The setting 
time is the time it takes the sample to begin hardening.  On the graph, it is the point 
where the exotherm peaks ends and flattens out. 
Two formulations using the original crush SilMix were investigated first.  Exo 1a-
b and Exo 2a-b samples had the same formulation (P1-6).  However, there was a 
difference in the length of time required for the addition of the catalyst; Exo 1a-b took 
two minutes longer than Exo 2a-b.  Exo 3a-b (P1-5) contained less LMC and PIH.  All of 
the samples completely polymerized at 30 min as determined by the GNT.  The samples 
with the highest exotherms were Exo 1a-b, which had setting times that were less than 
Exo 2 a-b.  This result made sense; with the same amount of catalyst, the faster setting 
time would result in a higher exotherm.  As for Exo 3a-b, the lower catalyst amount 
yielded the lowest exotherm and also the shortest setting time.  The formulations, max 
exotherms, and setting times are listed in Table 3.6 and the graph in Figure 3.1.  Besides 
the differences in exotherms and setting times, there was also a difference in appearance.  
The Exo 1 samples were very grainy, almost crystalline.  Upon observation, Exo 2 and 
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Exo 3 samples were much smoother, and the Exo 3 samples had a better consistency of 
the two (Figures 3.2 a-c).  All of these samples polymerized well below our 45 °C 
threshold. 
 
 
Table 3.6: Formulations, exotherms and setting times of P1-5 and P1-6.  
Sample %SM %PIH %LMC %CSM %DY5 Max ( °C ) Setting Time (s) 
Exo 1a (P1-6) 34.25 0.15 0.15 55.84 9.61 34.9 °C 128 s 
Exo 1b (P1-6) 34.25 0.15 0.15 55.84 9.61 35.3 °C 156 s 
Exo 2a (P1-6) 34.25 0.15 0.15 55.84 9.61 29.5 °C 247 s 
Exo 2b (P1-6) 34.25 0.15 0.15 55.84 9.61 32.7 °C 243 s 
Exo 3a (P1-5) 34.27 0.10 0.11 55.91 9.61 27.0 °C 88 s 
Exo 3b (P1-5) 34.27 0.10 0.11 55.91 9.61 27.0 °C 96 s 
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Figure 3.1: Plot of exotherms for P1.  
 
 
 
 
Figure 3.2: Pictures of Exo 1-3 
    
a) Exo 1   b) Exo 2   c) Exo 3 
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The exothermicity of the P1-m7 formulation (49.95 wt% SM, 0.10 wt% PIH, 0.10 wt% 
LMC, 35.85 wt% CSM, and 14.00 wt% DY5) was compared to light-cured SilMix 
(LCSM) and the PMMA-based bone cement, Simplex P.  The P1-m7 exotherm of 40 °C 
was significantly lower than the others (Figure 3.3).  All of the P1-5, P1-6 and P1-m7 
formulations passed the exothermicity screening test.  Since P1-m7 had a better texture 
and consistency, it next underwent mechanical testing. 
 
 
Figure 3.3: Exotherms of P1-m7, LCSM, and commercial bone cement. 
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P1 – Mechanical Testing  
As mentioned previously, flexural strength and flexural modulus are important 
factors for the development of a bone cement.  According to the ISO 5833 standards, a 
bone cement should have a flexural strength greater than 50 MPa and a flexural modulus 
greater than 1.8 GPa.  After passing the GNT, formulation P1-m6 and P1-m7 were 
selected for mechanical testing (Table 3.7) with Simplex P as the control.   
 
 
Table 3.7: Mechanical specimen formulations. 
Formulation %SM %PIH %LMC %CSM %DY5 
P1-m6 42.18 0.10 0.10 45.58 11.77 
P1-m7 49.95 0.10 0.10 35.85 14.00 
Simplex P n/a n/a n/a n/a n/a 
 
 
Samples were prepared and given to Dr. Melander at the UMKC School of Dentistry for 
testing.  Neither of the P1 samples performed as well as the Simplex P.  Both samples 
had flexural strengths essentially half of that of Simplex P (ISO 5833 standard > 50 MPa) 
but close to the desired flexural modulus (1.6 rather than >1.8 GPa according to the ISO 
5833 standard).  More details are found in Table 3.8 and Figures 3.4 a-b.  Due to the poor 
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strength results, it was decided to investigate the degree of conversion of the better 
performing P1 formulation, P1-m7  
 
 
Table 3.8: Flexural strength and modulus of Simplex P, P1-m6, and P1-m7. 
Formulation Flexural Strength (MPa) Flexural Modulus (GPa) 
P1-m6 22.26 1.58 
P1-m7 25.77 1.63 
Simplex P 52.69 2.17 
 
 
Figure 3.4: a) Flexural strength and b) modulus of Simplex P, P1-m6, and P1-m7. 
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P1 – Degree of Conversion (DC)  
At this point, one P1 formulation performed the best for all of the testing, P1-m7 
(49.95 wt% SM, 0.10 wt% PIH, 0.10 wt% LMC, 35.85 wt% CSM, 14.00 wt% DY5).  In 
order to explain the low strength of the formulations, the degree of conversion (DC) of P1 
was investigated using a sample of LCSM filled to 50 wt% with DY5 (filled 
photoinitiated) as the control.  This study was performed with Dr. Melander at the 
UMKC School of Dentistry.  The DC of P1-m7 (approximately 33%) was lower than that 
of the filled LCSM (56%), which was another setback with the P1 formulation (Figure 
3.5).   
 
 
Figure 3.5: Degree of conversion for filled LCMS and P1 (filled chemically initiated). 
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Disadvantages of P1 
There were three main problems with the P1 formulation.  The texture of the final 
material was very grainy due to the consistency of the powdered LCSM.  The second 
issue, low strength of the material (25.77 MPa), was also attributed to LCSM powder.  
Lastly, the desired handing properties were not achieved using this formulation.  When 
the sample had the desired handling time (5 – 10 min), the material was tacky and took 
longer than one hour to pass the GNT.  When the sample did pass the GNT in less than an 
hour, the handling time would decrease to less than five minutes at which time the 
material would begin to gel and could not be manipulated.  By increasing the LMC/PIH, 
it was possible to decrease the polymerization times and also, unfortunately, the handling   
The textual, strength, and handling issues led to the development of a new formulation, 
prototype 2 (P2).  
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Prototype 2 (P2) 
In order to improve the texture of the P1 system, the CSM was replaced with 
modified glass fillers previously tested with the SilMix (see Early Work section in 
Chapter 1).  In addition to the LMC and PIH (30), the other two components from ternary 
the light initiation system, CPQ (25) and EDMAB (27), were incorporated to help extend 
the handling time while shortening the total polymerization time.  The new initiation 
system was considered a mixed or dual cured system because it contained both chemical 
and light sensitive components.  However, unlike the previous mixed systems, the P2 
samples were not directly irradiated with a light source, instead only ambient light was 
used.  The differences between the components of commercial bone cement, prototype 1 
(P1), and prototype 2 (P2) are listed in Table 3.9.  The desired properties were the same 
as with the P1 and are listed in Table 3.10. 
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Table 3.9: Formulation comparison between PMMA, P1, and P2. 
PMMA FUNCTION Silorane  P1 P2 
Methyl methacrylate (1, 
32.3-33%) 
RESIN SilMix  35-55% 35-55% 
(LCSM) 
Pre-polymerized PMMA 
beads (2, 55.3-66%) 
FILLER CSM 36-56% 0% 
Barium sulfate/zirconium 
dioxide (6-10%) 
RADIOPACIFIER DY5  9-14% 35-74% 
(surface- 
treated 
N,N-dimethyl-p-toluidine 
(DMPT) (3, 0.13-0.93%) 
ACCELERATOR PIH 0.04-0.27% (in LCSM) 
Benzoyl peroxide (4, 0.5-
1.73%) 
INITIATOR LMC  0.11-0.30% 0.30-0.80% 
Hydroquinone (5, 5-25 
ppm) 
INHIBITOR N/A N/A N/A 
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Table 3.10: Desired properties of bone cement. 
  ISO 5833 Standard
57 Desired properties 
Exothermicity (°C) !90 !45 
Handling time (min) 3-15 !20 
Flexural modulus (GPa) "1.8 "1.8 
Flexural strength (MPa) "50 "50 
Compressive strength (MPa) "70 "70 
Pull out strength – mimic (MPa) n/a "4.5 
Pull out strength – ex vivo (MPa) n/a "4.5 
Pull out strength – in vivo (MPa) n/a "4.5 
Cytotoxicity (% cell death) n/a !20% 
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P2 – DY5 Formulations  
In the beginning of the P2 development, the first formulations investigated were 
filled with modified DY5 filler.  All three modifications identified in Chapter 1 (Early 
Work section), ECHE (45), 1TOSU (46), and 3TOSU (47), were utilized in this study.  
The formulations and their polymerization results are listed in Table 3.11.  While 
handling times should ideally be around 15 min, complete polymerization should occur 
between 30 min and one h as determined by the GNT. Those formulations that passed the 
GNT between 30 and 45 min underwent mechanical testing for flexural strength and 
flexural modulus.  These formulations are bolded in Table 3.11. 
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Table 3.11: P2 DY5 formulations and GNT results. 
Sample %SM %PIH %CPQ %EDMAB %LMC %DY5 DY5 mod. GNT Pass 
DY5-E-a 47.74 1.49 0.50 0.07 0.39 49.80 ECHE 1.5 h 
DY5-E-b 47.73 1.49 0.50 0.07 0.41 49.79 ECHE 1.25 h 
DY5-E-c 47.72 1.49 0.50 0.07 0.42 49.79 ECHE 45 min 
DY5-3T-a 47.72 1.49 0.50 0.07 0.42 49.79 3TOSU 15 min 
DY5-3T-b 47.74 1.49 0.50 0.07 0.38 49.81 3TOSU 1 h 
DY5-3T-c 47.73 1.49 0.50 0.07 0.40 49.80 3TOSU 45 min 
DY5-3T-d 37.81 1.18 0.39 0.06 0.56 59.99 3TOSU 30 min 
DY5-3T-e 37.76 1.18 0.39 0.06 0.62 59.99 3TOSU 45 min 
DY5-3T-f 23.22 0.73 0.24 0.04 0.84 74.93 3TOSU 15 min 
DY5-1T-a 37.72 1.18 0.39 0.06 0.65 60.00 1TOSU 15 min 
DY5-1T-b 37.77 1.18 0.39 0.06 0.58 60.01 1TOSU 15 min 
DY5-1T-c 38.05 1.19 0.40 0.06 0.30 60.01 1TOSU 45 min 
 
 
 
For the formulations that passed the GNT, flexural strength and flexural modulus were 
investigated using the four-point bend test (Table 3.12).  From the ISO 5833 standard, 
flexural strength is required to be greater than 50 MPa, and a flexural modulus is required 
to be greater than 1.8 GPa for a bone cement material.  Samples were prepared and given 
to Dr. Melander at the UMKC School of Dentistry for testing.   
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Table 3.12: Mechanical specimen formulations. 
Formulation %SM %PIH %CPQ %EDMAB %LMC %DY5 DY5 mod. 
DY5-E-c 47.72 1.49 0.50 0.07 0.42 49.79 ECHE 
DY5-3T-c 47.73 1.49 0.50 0.07 0.40 49.80 3TOSU 
DY5-3T-d 37.81 1.18 0.39 0.06 0.56 59.99 3TOSU 
DY5-3T-e 37.76 1.18 0.39 0.06 0.62 59.99 3TOSU 
DY5-1T-c 38.05 1.19 0.40 0.06 0.30 60.01 1TOSU 
 
 
In contrast to the P1 formulations (~1.6 GPa), all of the formulations exceeded the 1.8 
GPa threshold for flexural modulus. For the 3TOSU samples, there was a direct 
correlation of amount of filler to the modulus.  The flexural strength results revealed that 
there was a difference between the modifications as well as the wt% of filler.  The ECHE 
modification had the lowest strength, while the 1TOSU had the highest.  In fact, the 
DY5-1T-c formulation with a flexural strength of 59.53 ± 0.11 MPa was the best 
performing prototype of either P1 or P2, which was the first formulation to exceed the 
minimum strength of 50 MPa.  A summary of results can be found in Table 3.13 and 
Figures 3.6 a-b. 
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Table 3.13: Mechanical results. 
Formulation Flexural Strength (MPa) Flexural Modulus (GPa) n= 
DY5-E-c 24.80 ± 3.55 2.58 ± 0.26 9 
DY5-3T-c 37.62 ± 4.55 2.96 ± 0.18 6 
DY5-3T-d 37.36 ± 8.04 3.33 ± 0.38 7 
DY5-3T-e 37.03 ± 2.66 3.56 ± 0.13 3 
DY5-1T-c 59.53 ± 0.11 3.32 ± 0.24 2 
 
 
 
Figure 3.6: a) Flexural strength and b) modulus of initial DY5 P2 formulations. 
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Following this strength investigation, it was determined that the ideal composition would 
contain 60 wt% modified filler, 0.3 wt% LMC, and 39.7 wt% LCSM (SilMix with 
PIH/CPQ/EDMAB).  
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P2 – Biocompatibility  
The Trypan Blue (TB) Exclusion and MTT assays were used to determine 
biocompatibility.  As mentioned previously in Chapter 1 (Properties of Bone Cement and 
Standard Testing), TB measures cell death while MTT indicates cell viability.  For these 
studies, all samples were compared to two controls: empty cell wells and light-cured 
SilMix (LCSM) discs. As with all previous biocompatibility testing, post-osteoblast/pre-
osteocyte type cells, MLO-A5, were used.  Biocompatibility was performed for all of the 
components of P2.  The highest LMC limit tested before was approximately 0.10 wt%, 
compared to 0.46 wt% for the P2.   
The first P2 formulations were filled to 60 wt% with either 1TOSU or 3TOSU 
modified M12 (Table 3.14).  In addition to the positive controls, a negative control, 
PMMA commercial bone cement, was also used.  Along with TB assay of cells directly 
on the materials, the toxicity of potential leachables was tested using the MTT assay of 
cells in contact with media removed from disk wells.  Samples were prepared and given 
to Dr. Bi at the UMKC School of Dentistry for testing.   
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Table 3.14:  Formulations of samples for biocompatibility testing. 
Sample ID %SM %PIH %CPQ %EDMAB %M12 %LMC Modification 
P2 with 1TOSU (P2-1TOSU) 37.90 1.19 0.39 0.06 60.00 0.46 1TOSU 
P2 with 3TOSU (P2-3TOSU) 37.90 1.19 0.39 0.06 60.00 0.46 3TOSU 
Neat Light Cured SilMix 
(LCSM) 
95.85 3.00 1.00 0.15 0.00 0.00 N/A 
Zimmer Osteobond Copolymer 
Bone Cement (PMMA) 
N/A N/A N/A N/A N/A N/A N/A 
 
 
 
As with previous biocompatibility screening for the silorane systems (LCSM and 
LMC/PIH), the P2 samples were biocompatible.  There was no significant difference in 
the percent live/dead from the empty well control and the silorane formulations (Table 
3.15).  But there was a difference observed for the PMMA samples, which was expected 
(Figures 3.7 a-b).  As for the leachable study, there was a difference between the P2 
samples and the three controls (p<0.05), but not significant to be of a concern (Figure 
3.8).  These results show that this new formulation, P2-M12 with the three different 
modifications, was biocompatible. 
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Table 3.15:  Percent live vs. dead cells at 24 and 48 h. 
Sample ID %Live – 24 h %Dead – 24 h %Live – 48 h %Dead – 48 h 
Control 96.4 3.6 96.8 3.2 
PMMA 71.7 28.3 84.0 16.0 
LCSM 94.4 5.6 95.6 4.4 
P2-1TOSU 94.2 5.8 95.2 4.8 
P2-3TOSU 93.1 6.9 93.1 6.9 
 
 
 
Figure 3.7: Percent live vs. dead cells at a) 24 h and b) 48 h 
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Figure 3.8: MTT assay results for potential leachables. 
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formulation with 60 wt% 1TOSU-modified DY5 glass.  This formulation was compared 
to empty cell wells, P2 with 60 wt% 1TOSU-modified M12 glass, and a commercial bone 
cement, Simplex P (Table 3.16).  This study was performed by Dr. Bi at the UMKC 
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Table 3.16: Formulations tested. 
Sample ID %SM %PIH %CPQ %EDMAB %Filler %LMC Modification 
Simplex P (PMMA) N/A N/A N/A N/A N/A N/A N/A 
P2 – 1TOSU mod DY5 37.90 1.19 0.39 0.06 60.00 0.46 1TOSU 
P2 – 1TOSU mod M12 37.90 1.19 0.39 0.06 60.00 0.46 1TOSU 
 
 
As with the previous results for P2 with M12 glass, only one sample the Simplex P 
samples were significantly different from the empty well control and had higher toxicity 
than the other samples. The results are given in Table 3.17 and Figures 3.9. 
 
 
Table 3.17: Percent live/dead cells at 24 and 48 h. 
Sample ID %Live – 24 h %Dead – 24 h %Live – 48 h %Dead – 48 h 
Control 97.9 2.1 97.3 2.7 
PMMA 88.8 11.2 91.7 8.3 
1TOSU DY5 96.9 3.1 96.7 3.3 
1TOSU M12 96.5 3.5 96.6 3.4 
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Figure 3.9: Percent live vs. dead cells a) 24 h and b) 48 h. 
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P2 – Pull Out Strength 
After the biocompatibility of P2 formulation was determined and the amount 
LMC was optimized, the pull out strength was investigated using a rat model (Table 
3.18).  It measures the ability of a material to fix a titanium rod in a femur.   
 
 
Table 3.18:  Ex vivo pull out sample formulations. 
Sample ID %SM %PIH %CPQ %EDMAB %LMC %Filler 
Simplex P  N/A N/A N/A N/A N/A N/A 
P2 – 1TOSU mod M12 37.90 1.19 0.39 0.06 0.46 60.00 
P2 – old 1TOSU mod DY5 37.90 1.19 0.39 0.06 0.46 60.00 
 
 
A hole drilled was drilled down the center of the femur at the distal end.  The formulation 
was injected into the hole, and then an acid etched titanium rod  (22 mm x 1.5 mm) was 
inserted.  For this test, the target desired strength was equal to or greater than 4.5 MPa.  
More information on the pull out procedure can be found in the Materials and Methods 
section.  For ex vivo testing, excised rat bones from previously sacrificed animals and 
etched Ti rods (22 mm x 1.5 mm) were used.  P2 formulations (1TOSU M12 and 1TOSU 
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DY5) and Simplex® P (Table 3.18) were compared using this ex vivo model.  Samples 
were prepared in collaboration with Dr. Bi, who also conducted the measurements.  
The initial results were extremely disappointing because P2 formulations had a 
fraction of the pull out strength of Simplex P, 0.53 and 0.70 MPa compared to 3.08 MPa 
(Table 3.19 and Figure 3.10).  It is interesting to note that the Simplex P samples did not 
even meet the minimum criteria of 4.5 MPa.  Because of this result, the minimum pull 
out strength for the P2 formulations was reduced to equal to or greater than 70% of the 
PMMA control’s pull out strength for screening purposes. 
 
 
Table 3.19: Ex vivo pull out strengths of Simplex P and P2 formulations.  
 
Sample ID Pull Out Strength (MPa) 
Simplex P 3.08 ± 0.14 
1TOSU M12 0.56 ± 0.18 
1TOSU DY5 0.70 ± 0.35 
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Figure 3.10:  Ex vivo pull out strengths of Simplex P and P2 formulations. 
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P2 – Pull Out Mimic 
Unfortunately, there were two limitations to the ex vivo rat mode study, the cost 
and number of rat femurs.  Therefore, a mimic rat put out test was developed.  It was 
basically a small tube with an inner diameter of 3 mm that was scored and then imbedded 
in the specimen holder.  The tube was filled with the test formulation, and then the Ti rod 
was inserted.  This mimic setup was used mostly for consistency and product control by 
comparing batches of catalysts, fillers, and modifications.  Additional details of the pull 
out mimic setup are described in the Material and Methods section.   
In order to determine the differences between the glasses, pull out mimic samples 
were prepared using the ECHE-modified fillers at 60 wt% and 0.32 wt% LMC using 
Simplex P as the control.  These samples were tested by Dr. Bi (Table 3.20).   
 
 
Table 3.20:  Pull out mimic: M12/DY5 comparison formulations. 
Sample ID %SM %PIH %CPQ %EDMAB %LMC %Filler 
Simplex P  N/A N/A N/A N/A N/A N/A 
P2 with ECHE mod M12 
(ECHE M12) 
38.03 1.19 0.40 0.06 0.32 60.00 
P2 with ECHE mod DY5 
(ECHE DY5) 
38.03 1.19 0.40 0.06 0.32 60.00 
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It was found that there was no significant difference between any of the samples.  
Therefore, there was no difference between the glasses in the same P2 system (Table 3.21 
and Figure 3.11).  These formulations were investigated further with mechanical and ex 
vivo pull out tests. 
 
 
Table 3.21: Pull out mimic strength: M12/DY5 comparison. 
Sample ID Pull Out Strength (MPa) 
Simplex P 5.64 ± 0.09 
ECHE M12  5.44 ± 0.43 
ECHE DY5  5.85 ± 0.52 
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Figure 3.11: Pull out mimic strength: M12/DY5 comparison. 
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P2 – ECHE Formulations 
Since the mimic was successful, the next step was to investigate ECHE 60 wt% 
filled with 0.32 wt% LMC system.  The flexural strength, flexural modulus, compressive 
strength, and pull out strength were preformed using excised rat bones.  The same sample 
formulations were used for all of these tests, and details can be found in Table 3.22.  For 
the investigation of flexural strength and flexural modulus, the four-point bend test was 
used.  Compressive strength was tested according to ISO 5833.  The samples were 
compared with the commercial bone cement, Simplex P.  Specimens were prepared in the 
laboratory and transferred to Dr. Melander at the School of Dentistry for testing.  
 
 
 
Table 3.22: Mechanical specimens – ECHE formulations. 
Sample ID %SM %PIH %CPQ %EDMAB %LMC %Filler 
Simplex P  N/A N/A N/A N/A N/A N/A 
P2 with ECHE mod M12 
(ECHE M12) 
38.03 1.19 0.40 0.06 0.32 60.00 
P2 with ECHE mod DY5 
(ECHE DY5) 
38.03 1.19 0.40 0.06 0.32 60.00 
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Table 3.23: Flexural strength and modulus – ECHE formulations. 
Sample ID Flexural Strength 
(MPa) 
Flexural Modulus 
(GPa) 
Compressive Strength 
(MPa) 
Simplex P 61.20 ± 2.99 2.44 ± 0.24 78.63 ± 1.41 
ECHE M12  40.50 ± 3.46 3.10 ± 0.09 83.17 ± 8.75 
ECHE DY5  35.46 ± 4.90 3.03 ± 0.19 90.92 ± 2.95 
 
 
The flexural strength of this formulation did not meet the ISO 5833 threshold of greater 
than 50 MPa; however, these samples were closer than the original ECHE DY5 P2 
formulation tested (approximately 25 MPa).  As for the flexural modulus, all of the 
samples exceeded the minimum requirement of 1.8 GPa.  For compressive strength, all 
samples were greater than 70 MPa as required by the ISO.  The mechanical results can be 
found in Table 3.23 and Figure 3.12.   
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Figures 3.12: Results of ECHE formulations for a) flexural strength, b) flexural modulus, 
and c) compressive strength. 
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After the mechanical testing of flexural strength, flexural modulus, and 
compressive strength, the same formulations (Table 3.22) were used for ex vivo pull out 
testing by Dr. Bi.  As with the mechanical testing, a PMMA control was used (Simplex 
P).  It was determined that the pull out strengths for our ECHE P2 formulations were 
significantly lower than the PMMA control (Table 3.44 and Figure 3.13).  All the 
samples including the control were lower in the ex vivo test than in the previous pull out 
mimic.  When comparing these results to previous ex vivo work, the PMMA controls 
were similar.  On the other hand, these results for the P2 formulations were higher than in 
the earlier ex vivo tests.   
 
 
 
Table 3.24: Ex vivo pull out strength – ECHE formulations. 
Sample ID Pull Out Strength (MPa) 
Simplex P 3.20 ± 0.77 
ECHE M12  1.53 ± 0.55 
ECHE DY5  1.90 ± 0.40 
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Figure 3.13: Ex vivo pull out strength – ECHE formulations. 
  
 
 
 
While the mimic screening test did result in an improved ex vivo result, it was not a 
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P2 –In Vivo Small Animal Model 
The next step was to take the best biocompatible formulations to in vivo testing in 
small animals.  Mice and rats are the most common small animal model.  A rat model 
was identified due to their larger size, which allows for easier surgeries.  From these live 
animals tests, both inflammation at the surgical site and pull out strengths would be tested 
8 weeks post surgery.  The surgeries were performed at the UMKC Laboratory Animal 
Research Core (LARC) with our Dental School collaborator, Dr. Lian Xiang Bi.  During 
surgery, the cement formulations were injected into the femoral canal, and then an acid 
etched titanium rod was inserted.  The rats were sacrificed either one or eight weeks after 
surgery.  
Three formulations were initially studied, and all of then were filled to 60 wt% 
with either ECHE M12 (n=20), ECHE DY5 (n=15), or 1TOSU DY5 (n=15).  A Simplex 
P control was also tested (n=10).  The cement compositions can be found in Table 3.25. 
Animals were sacrificed at two time points.  The animals used for histology and 
inflammation studies were sacrificed one-week post surgery.  Those rats used for the pull 
out tests were sacrificed 8 weeks post surgery.  Once the operated femur was removed, 
the Ti rod was exposed, and the pull out test was performed.   
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Table 3.25: Formulations of materials used in vivo. 
Sample ID %SM %PIH %CPQ %EDMAB %LMC %Filler Mod. 
Simplex P  N/A N/A N/A N/A N/A N/A N/A 
P2 with ECHE modified 
M12 (ECHE M12) 
38.03 1.19 0.40 0.06 0.32 60.00 ECHE 
P2 with ECHE modified 
DY5 (ECHE DY5) 
38.03 1.19 0.40 0.06 0.32 60.00 ECHE 
P2 with 1TOSU modified 
DY5 (1TOSU DY5) 
38.03 1.19 0.40 0.06 0.32 60.00 1TOSU 
 
 
It was found that the P2 samples only had between 9 and 22% of the strength of the 
commercial control, Simplex P, which was well below the desired 70%.  These results 
were unexpected. However, there was a decrease in inflammation observed around the 
surgical site for the P2 formulations.  Also, the animals with the P2 formulations lost less 
weight than the Simplex P animals.  However, the low strength was a significant problem 
that needed to be addressed before moving forward.  A summary of the pull out results 
can be found in Table 3.26 and Figure 3.1.   
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Table 3.26: In vivo pull out strength – ECHE formulations. 
Sample ID Pull Out Strength (MPa) 
Simplex P 2.79 ± 0.40 
ECHE M12  0.25 ± 0.07 
ECHE DY5  0.29 ± 0.09 
1TOSU DY5  0.62 ± 0.10 
 
 
 
Figure 3.14: In Vivo pull out strength – 8 weeks PO. 
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P2 – Putty Formulation 
It is known that an increase in filler is directly proportional to an increase in 
mechanical strength in dental composites.35  So in order to improve the mechanical 
properties of the P2 formulation, a studied was performed, which investigated the optimal 
amount of  modified filler.  With an increase in filler, the optimal, amount of LMC was 
modified to address any changes in handling or polymerization times.  The first material 
was a putty with amounts of 1TOSU DY5 ranging from 65 – 75 wt%s and 0.36 – 0.70 
wt%s for LMC.  The GNT was used to test for polymerization time.  The handling 
properties were investigated with respect to two points: the time it took for the material to 
be worked into a ball and the second time point when the ball was unable to be 
manipulated further.  The summary of the putty formulations and handling times can be 
found in Tables 3.27 and 3.28. 
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Table 3.27:  Putty formulations and polymerization test results. 
Formulation %SM %PIH %CPQ %EDMAB %Filler %LMC GNT Pass 
Putty 1 (65% filled) 32.92 1.03 0.34 0.05 65.00 0.65 30 min 
Putty 2 (65% filled) 33.07 1.04 0.35 0.05 65.00 0.50 30 min 
Putty 3 (65% filled) 33.16 1.04 0.35 0.05 65.00 0.40 30 min 
Putty 4 (65% filled) 33.20 1.04 0.37 0.05 65.00 0.36 45 min 
Putty 5 (67% filled) 30.96 0.97 0.32 0.05 67.00 0.70 15 min 
Putty 6 (67% filled) 30.96 0.97 0.32 0.05 67.00 0.70 15 min 
Putty 7 (70% filled) 28.08 0.88 0.29 0.04 70.00 0.70 30 min  
Putty 8 (70% filled) 28.13 0.88 0.29 0.04 70.00 0.65 30 min 
Putty 9 (75% filled) 23.29 0.73 0.24 0.04 75.00 0.70 45 min 
Putty 10 (75% filled) 23.29 0.73 0.24 0.04 75.00 0.70 45 min 
Putty 11 (75% filled) 23.29 0.73 0.24 0.04 75.00 0.70 45 min 
Putty 12 (75% filled) 23.29 0.73 0.24 0.04 75.00 0.70 45 min 
Putty 13 (75% filled) 23.58 0.74 0.25 0.04 75.00 0.40 30 min 
Putty 14 (70% filled) 28.42 0.89 0.30 0.04 70.00 0.35 30 min 
Putty 15 (72.5% filled) 26.02 0.81 0.27 0.04 72.50 0.35 30 min 
Putty 16 (74% filled) 24.58 0.77 0.26 0.04 74.00 0.35 30 min 
Putty 17 (74.5% filled) 24.10 0.75 0.25 0.04 74.50 0.35 45 min 
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Table 3.28: Handling properties of Putty samples. 
Putty ID Time to Form Ball  Time Ball Unworkable 
Putty 1 2.5 min 4.5 min 
Putty 2 3.5 min 4.5 min 
Putty 3 4.5 min 6.5 min 
Putty 4 4.5 min 5 min 
Putty 5 3.5 min 4.5 min 
Putty 6 3.5 min 4.5 min 
Putty 7 3.5 min 5 min 
Putty 8 3 min 4 min 
Putty 9 Immediately 6.5 min 
Putty 10 Immediately 6.5 min 
Putty 11 Immediately 6.5 min 
Putty 12 Immediately 6.5 min 
Putty 13 Immediately 5.5 min 
Putty 14 4.5 min 6 min 
Putty 15 6 min 7.5 min 
Putty 16 5 min 10.5 min 
Putty 17 3.5 min 7 min 
!
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Two formulations were identified as potential candidates, a thick material (74 
wt% 1TOSU DY5, 0.35 wt% LMC) and a thinner material (65 wt% 1TOSU DY5, 0.40 
wt% LMC).   Both of these materials passed the GNT at 30 min.  For the handling 
properties, the thinner material (Putty A) took 4.5 min to form a ball after the LMC was 
added and a total of 6.5 min when the ball could no longer be manipulated.  In the case of 
the thicker material (Putty B), the times were 5 min and 10.5 min, respectively.  It was 
decided to moved forward with in vivo pull out tests using Putty A (thinner material) and 
Putty B (thicker material). 
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P2 – Putty In Vivo Pull Out  
For the comparison of Putty A and B, a rat model utilizing both femurs of six 9-
month-old rats was used.  In addition to Putty A and B, “regular” P2 and Simplex P were 
also used (n=3).  The formulations and placements of the materials can be found in Table 
3.29.  To improve the handling and injection times of the Putty, a protocol was 
developed.  The dental syringe was assembled properly, the tip made readily available, 
and the Ti rod was placed next to the rat before the LMC was weighed.  When the LMC 
was added, the lamp above the surgical table was turned off until the Putty was injected.  
Once the material was placed in the syringe, it was used immediately.  These changes 
allowed for the Putty samples to be placed without any problems premature 
polymerization. 
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Table 3.29:  Formulations of samples for in vivo testing.   
Sample ID Rat/Leg %SM %PIH %CPQ %EDMAB %Filler %LMC 
Simplex P #1/R N/A N/A N/A N/A N/A N/A 
Putty B – 1TOSU DY5 #1/L 24.58 0.77 0.26 0.04 74.00 0.35 
Putty A – 1TOSU DY5 #2/R 33.16 1.04 0.35 0.05 65.00 0.40 
P2 – 1TOSU DY5 #2/L 38.03 1.19 0.40 0.06 60.00 0.32 
Simplex P #3/R N/A N/A N/A N/A N/A N/A 
Putty B – 1TOSU DY5 #4/L 24.58 0.77 0.26 0.04 74.00 0.35 
Putty A – 1TOSU DY5 #3/L 33.16 1.04 0.35 0.05 65.00 0.40 
P2 – 1TOSU DY5 #4/R 38.03 1.19 0.40 0.06 60.00 0.32 
Simplex P #5/R N/A N/A N/A N/A N/A N/A 
Putty B – 1TOSU DY5 #6/R 24.58 0.77 0.26 0.04 74.00 0.35 
Putty A – 1TOSU DY5 #6/L 33.16 1.04 0.35 0.05 65.00 0.40 
P2 – 1TOSU DY5 #5/L 38.03 1.19 0.40 0.06 60.00 0.32 
 
 
The animals were sacrificed one week after surgery, and the femurs were 
harvested.  Later that day, the pull out tests were performed by Dr. Bi.  While all of the 
silorane samples were below Simplex P strengths, Putty A had the best silorane in vivo 
strength, 3.75 MPa (Table 3.30 and Figure 3.15).  
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Table 3.30:  In vivo P2 vs. Putty A & B pull out strength – 1 week PO 
 Formulation Pull Out Strength (MPa) 
Simplex P 6.75 ± 1.02 
P2 – 1TOSU DY5 2.59 ± 0.99 
Putty A – 1TOSU DY5 3.75 ± 0.47 
Putty B – 1TOSU DY5 1.92 ± 0.34 
 
 
 
Figure 3.15:  In vivo P2 vs. Putty A & B pull out strength – 1 week PO 
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Because of these results, it was determined that only the 65 wt% filled Putty A would be 
used in all future work.  However, the strength did not meet the desired criterion.  After 
further reflection and discussion with collaborators, it was decided to focus on the 
“dryness” of the components of the formulations.  It may be a minor change but could 
have a large impact. 
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P2 – Moisture Investigation 
After the last set in vivo results, our collaborator Dr. Schuman, at MS&T, began 
investigating the role moisture played in the mechanical properties and cure kinetics of 
our SilMix.69  Previously, the amount of water was present in SilMix did not appear to 
interfere with the basic polymerization, exotherm, or mechanical tests.  However, when 
additional water was added to the system, there was a decrease in polymerization and 
strength.  While water did not seem to affect polymerization, too much water appeared to 
slow down the rate of the reaction.69  This result would explain the differences observed 
between the in vivo, ex vivo, and mimic pull out test results.  
The idea was to remove as much water from the different components of the 
system as possible.  The Ti rods were stored in a desiccator after autoclaving, the filler 
was kept under inert atmosphere once it was modified, and residual water was removed 
from SilMix.  It was assume that the removal of as much moisture from the system prior 
to its use, any water introduced would not have a significant effect on the polymerization. 
Dr. Schuman (MS&T) was able to reduce the water content of the silorane resin 
using a toluene-water azeotrope and a vacuum pump.  The water content was determined 
using Karl Fischer titration.  Before drying, the average water content was 0.18 wt%, 
while after drying, it decreased to approximately 0.1 wt% for dry and 0.03 wt% for ultra-
dry SilMix.69  For future testing, the dry SilMix (0.1 wt% ) was chosen due to the better 
degree of conversion 69  The dry components were tested in vivo next. 
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P2 – In Vivo Pull Out Dried Putty 
After the moisture study performed by Dr. Schuman, the dried material was 
investigated in a wet environment.  Samples were prepared to compare the original 60 
wt% filled material to the same formulation but using dried materials.  Putty A was also 
tested using the dry materials.  Fifteen 10-month-old rats underwent surgery on their right 
femurs.  As with all rat surgeries, they were performed at the LARC with Dr. Bi.  
Formulations containing Simplex P, Original P2 (60 wt%), Dry Original P2 (60 wt%), 
and Dry Putty A (65 wt%) were tested (n=3).  “Dry” meant that the filler and SilMix 
were dried, and a desiccated Ti rod was used.  For more information on the formulations 
and placements of these samples see Table 3.31. 
 
 
Table 3.31: Sample information for in vivo testing of “dried” material. 
Sample ID %SM %PIH %CPQ %EDMAB %Filler %LMC 
Simplex P N/A N/A N/A N/A N/A N/A 
Original P2 (60%) 38.03 1.19 0.40 0.06 60.00 0.32 
Dry Original P2 (60%) 38.03 1.19 0.40 0.06 60.00 0.32 
Dry Putty A (65%) 33.16 1.04 0.35 0.05 65.00 0.40 
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One week after surgery, the animals were sacrificed, and the femurs were 
harvested.  The pull out tests were performed that same day by Dr. Bi.  It was found that 
there was no significant difference between Simplex P and Dry Putty A formulations.  
The dry P2 samples were stronger than the regular P2 samples (Table 3.32 and Figure 
3.16).  From these results, the Dry Putty A formulation was chosen for future testing.   
 
 
 
Table 3.32:  In vivo pull out strength of dry material investigation – 1 week PO. 
 Formulation Pull Out Strength (MPa) 
Simplex P 4.08 ± 1.31 
Original P2 (60%) 1.68 ± 0.73 
Dry Original P2 (60%) 2.58 ± 0.56 
Dry Putty A (65%) 4.44 ± 0.85 
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Figure 3.16:  In vivo pull out strength of dry material investigation – 1 week PO. 
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P2 – In Vivo 8 weeks Pull Out Dried Putty  
Surgery was performed on the right femurs of seventeen 13-month-old rats at the 
LARC with Dr. Bi.  Dry Putty A (n = 9) was compared to Simplex P (n = 8).  The sample 
information can be found in Table 3.33. 
 
 
Table 3.33:  Sample information for in vivo testing. 
Sample ID %SM %PIH %CPQ %EDMAB %Filler %LMC 
Simplex P N/A N/A N/A N/A N/A N/A 
Dry Putty A (65%) 33.16 1.04 0.35 0.05 65.00 0.40 
 
 
Over the course of the eight weeks, four rats died or were sacrificed (one Simplex 
P and three Putty A).  This was the first time that there was a post-operative death of an 
animal from the SilMix group.  Necropsies were done, and any issues were attributed to 
the age of the animals.  With the previous in vivo testing, younger 9-10 month old rat 
were used.  After the deaths, there were only five Putty A and seven Simplex P animals.  
At the end of 8 weeks, the animals were sacrificed, and the femurs were harvested.  The 
pull out test was done later the same day.  While pull out strengths for Putty A were 
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lower than for Simplex P, the two groups were not statistically different (Table 3.34 and 
Figure 3.17). 
 
 
Table 3.34:  In vivo Simplex P vs. Putty A pull out strength – 8 weeks PO. 
 Formulation Pull Out Strength (MPa) 
Simplex P  6.28 ± 0.44 
Dry Putty A (65%) 4.94 ± 0.73 
 
 
 
Figure 3.17:  In vivo Simplex P vs. Putty A pull out strength – 8 weeks PO. 
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In summary from all of the in vivo data for dry Putty A (33.16 wt% SM, 1.04 wt% PIH, 
0.35 wt% CPQ, 0.05 wt% EDMAB, 65 wt% 1TOSU DY5, and 0.40 wt% LMC), a viable 
bone cement with comparable strength to Simplex P was found.  This formulation met or 
exceeded the desired requirements for the in vivo studies.  With the exception of Flexural 
Strength, Putty A met or exceeded the ISO standard 5833. With this, the next step for this 
material was large animal testing.   
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P2 – In Vivo Large Animal Model 
Swine were chosen for their similarity to humans in regards to orthopedics.  
Surgery was performed by Dr. Donna Pacicca on 16 pigs (n=8 each Simplex P and Dry 
Putty A) at the National Swine Research and Resource Center, Columbia MO.  The 
surgery protocol was similar in nature to the rat studies with the exception of the use of a 
larger implant (100 mm x 6.35 mm vs. 22 mm x 1.5 mm for the rat) and larger cement 
delivery device.  The animals were sacrificed at 8 weeks after surgery.  The histology and 
pull out studies were ongoing during the preparation of this dissertation.  
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Summary 
At the start of this research, numerous initiation systems were investigated for the 
formulation of a bone cement alternative.  However, only two exhibited potential for this 
purpose.  The first candidate was a filled mixed system of AA:PIH:CPQ (3:3:1 wt%s) 
filled to 50 wt% with DY5 and ECHE modified ANF (1:1 by wt).  Unfortunately, the 
requirement of direct irradiation with an external light source for polymerization limited 
its applicability for internal use..  The other alternative was a neat pure chemical option 
of LMC/PIH (0.07 wt% LMC and 0.04 wt% of PIH), which did not require irradiation for 
polymerization.  This formulation was biocompatible, and the handling and 
polymerization times were within the acceptable range, approximately five and 30 min, 
respectively.  It was utilized for the generation of prototype 1 (P1), which contained 
SilMix (CSM) and glass filler in addition to the LMC/PIH initiation system.  There were 
drawbacks with P1, which included the grainy consistency of the material, low flexural 
strength of (25.8 MPa), and poor handling properties.  Due to these issues, prototype 2 
(P2) was developed, which was comprised of a mixed initiation system, LMC/LIS (PIH, 
CPQ, EDMAB) and polymerized without the use of direct irradiation from an external 
light source.  With respect to consistency, it was improved with P2 due to the removal of 
the CSM and an increase in glass filler.  Further investigations with P2 with respect to the 
filler were performed with either M12 or DY5 glass with one of three modifications 
(ECHE, 1TOSU, and 3TOSU).  All of the components in P2 formulations had good 
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biocompatibility and low polymerization exothermicity, however the in vivo pull out 
strengths were well below the desired threshold of " 70% of the PMMA control’s pull 
out strength.  Due to results of the moisture study, a bone cement alternative, Dry Putty A 
formulation (33.16 wt% SM, 1.04 wt% PIH, 0.35 wt% CPQ, 0.05 wt% EDMAB, 65 wt% 
1TOSU DY5, and 0.40 wt% LMC), was identified.  This formulation met all of the 
desired properties of biocompatibility, in vivo pull out strength, low exothermicity upon 
polymerization, and lack of inflammation response at surgical site.  There were no 
complications resulting from the use of this material in 8 swine and over 50 rat subjects.  
The summary of the P2 bone cement alternative properties is found in Table 3.35. 
The future work on this project will be in the areas of therapeutic beads and 
spacers, as well as, studies of the incorporation of antibiotics and antifungals into this 
material.  Due high polymerization temperature of commercial PMMA bone cement, the 
number of antibiotics that can be incorporated for the treatment of infection is limited to 
those that are heat stable.  With a low polymerization exotherm, a wider variety of 
antibiotics may be incorporated into the P2 alternative.   From initial elution studies of 
vancomycin into P2, it provided proof of concept that antibiotics can be incorporated into 
Putty A and with similar elution profiles to that of Simplex P.   
 
 
 
 178 
Table 3.35: Summary of P2 properties. 
  
ISO 5833 
Standard57 
Desired 
properties 
P2 
(60 & 65% filled) 
Exothermicity (°C) !90 !45 26 ± 0.5 
Handling time (min) 3-15 !20 8-10 
Flexural modulus (GPa) "1.8 "1.8 3.1 
Flexural strength (MPa) "50 "50 40.5 
Compressive strength (MPa) "70 "70 90.9 
Pull out strength – mimic 
(MPa) n/a "4.5 4.1 
Pull out strength – ex vivo 
(MPa) n/a "4.5 2.0 
Pull out strength – in vivo 
(MPa) n/a "4.5 4.9 
Cytotoxicity (% cell death) n/a !20% <5% !!! !
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APPENDIX A 
MATERIALS AND METHODS 
 
 
 
Materials 
SilMix is a 1:1 combination by wt ratio of PHEPSI (bis[2-(3{7-
oxabicyclo[4.1.0]heptyl})-ethyl]methylphenyl silane) and CYGEP (2,4,6,8-tetrakis(2-(7-
oxabicyclo[4.1.0]heptan-3-yl)ethyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxa-
tetrasilocane).  The general reaction schemes for the synthesis of the two monomers are 
given below and described in Dr. Bradley Miller’s dissertation.62  1H and 13C NMR 
spectra were recorded on a Varian INOVA 400 MHz nuclear magnetic resonance 
spectrometer operating at 399.8 MHz and referenced to CDCl3 (Cambridge Isotopes).  
Unless otherwise noted, commercial chemicals were used as supplied without further 
purification.  Starting materials were obtained from the following sources: 
methylphenylsilane (Gelest); 4-vinyl-1-cyclohexene-1,2-epoxide (Aldrich); and 2,4,6,8-
tetramethylcyclotetrasiloxane and Wilkinson’s Catalyst (Alfa Aesar).  Lamoreaux’s 
catalyst was synthesized from an adapted procedure by Lamoreaux.62,70   
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Bis[2-(3{7-oxabicyclo[4.1.0]heptyl})-ethyl]methylphenyl silane (PHEPSI)62,71  – 
PHEPSI was prepared according to an adapted procedure from Crivello.  1H NMR 
(CDCl3, 399.8 MHz) δ 0.21 (s, 3H), 0.71 (m, 4H), 0.78-2.20 (m, 18H), 3.11 (m, 4H), 7.34 
(m, 3H), 7.45 (m, 2H) ppm; 13C NMR (CDCl3, 100.5 MHz) δ 10.6, 10.8, 23.5, 23.9, 25.1, 
26.7, 29.9, 30.1, 30.5, 31.5, 32.4, 35.2, 51.8, 52.6, 53.1, 127.6, 128.7, 133.6, 138.0 ppm.   
 
 
PHEPSI reaction scheme 
 
 
 
2,4,6,8-tetrakis(2-(7-oxabicyclo[4.1.0]heptan-3-yl)ethyl)-2,4,6,8-tetramethyl-
1,3,5,7,2,4,6,8-tetraoxa-tetrasilocane (CYGEP)62,72  – CYGEP was prepared according to 
an adapted procedure from Aoki.  1H NMR (CDCl3, 399.8 MHz) δ 0.02 (s, 12H), 0.44 (s, 
8H), 0.79-2.18 (m, 36H), 3.12 (m, 8H) ppm; 13C NMR (CDCl3, 100.5 MHz) δ 13.9, 23.5, 
24.0, 25.2, 26.8, 29.2, 29.8, 30.3, 31.5, 32.0, 35.0, 51.8, 52.2, 53.5 ppm. 
 
O
H2
Si Si
O O
+
Toluene
RhCl(Ph3P)3
2 equivalents
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CYGEP reaction scheme: 
 
 
 
Lamoreaux’s catalyst (LMC)62,70 – LMC was prepared according to an adapted 
procedure from Lamoreaux and not characterized.   
 
 
LMC reaction scheme 
 
 
 
 
O
SiO
Si
O
Si O
Si H
H
H
H O
O Si
O
Si
OSi
O
Si
O
O
O
O
+ Lamoreaux catalyst
Toluene
4 equivalents
H2PtCl6 . 6H2O + OH PtCl2 Complex50°C
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Sample Preparation Methods 
For neat light-cured SilMix (LCSM): SilMix (SM) was combined with the p-
(octyloxyphenyl)phenyliodonium hexafluoroantimonate) (PIH), camphorquinone (CPQ), 
and ethyl p-dimethylaminobenzoate (EDMAB) in a high-speed mixer until no particles 
were visible (between 30 min to an hour depending on the amount of material).  The final 
composition of the LCSM was 95.85 % SM, 3.0 % PIH, 1.0 %, CPQ, and 0.15 % 
EDMAB (by total weight of sample). 
For filled Light Cured samples: LCSM was combined with the filler at the wanted 
amount and mixed in a high-speed mixer between 15 and 30 minutes depending on the 
amount of material.  
Neat Chemical Cure of SM:  SilMix (1 g) and the acid catalyst were combined 
using a FlackTek Speed Mixer and mixed for 5 min.   
Neat Dual Cure samples:  SilMix (1.5 g) and the photosensitive compound(s) of 
the initiation system were combined using a FlackTek Speed Mixer and mixed for 
periods of 5 – 30 min depending on the amount of material.  Then, the acid catalyst 
component was added, and the sample was mixed for another 5 – 10 min depending on 
the amount of catalyst. 
For filled Dual Cure samples:  Samples were prepared by combining SilMix (1.5 
g) and the photosensitive compound(s) of the initiation system using a FlackTek Speed 
Mixer and mixed for periods of 5 – 30 min depending on the amount of material.   Then, 
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filler (1:1 by wt) was added and mixed in a high-speed mixer between 15 and 30 minutes 
depending on the amount of material. Finally, the acid catalyst component was added, 
and the sample was mixed for another 5 – 10 min depending on the amount of catalyst. 
Crushed SilMix (CSM) for prototype 1 (P1) samples:  LCSM was polymerized on 
glass slide.  At first the polymer was ground using a coffee grinder to start and then a 
mortar and pestle.  In order to attain more uniform particles, the samples were milled 
(MS&T collaborators).  
For Prototype 1 (P1) samples:  In one cup, the CSM was combined with the filler 
and mixed in the mixer on high for 1 min.  In another cup, SM and PIH were mixed for 
15 min.  The dry components were added to the wet components and mixed by hand.  
Finally the LMC was added using a needle and syringe (by weight on a balance) and 
mixed by hand for approximately 30 sec. 
For Prototype 2 samples (silorane bone cement):  Light-cured SilMix (LCSM) 
was prepared as stated previously.  A portion of the LCSM was combined with the glass 
filler and mixed in the high-speed mixer (approximately 25 min). The material was 
allowed to cool to room temperature, and then the Lamoreaux Catalyst (LMC) was added 
using a needle and syringe (by weight on a balance) and mixed by hand for 
approximately 30 sec. 
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Sample Test Methods 
Gilmore Needle test:  The one – lb. needle was placed on the sample (~ 0.1 g) and 
then removed.  If a needle indented or marked the sample,, then the sample “failed”; if no 
mark or indentation was observed, then the sample “passed”.  
pH test:  The pH of the deionized or distilled water (~60 mL) was taken initially 
by placing a pH probe in the beaker, waiting five min, and then taking the reading.   
Then, a polymerized sample (~60 mg) was placed in the water.  The resulting pH of the 
water containing the sample was then measured at 15-min increments for the first h. 
Exotherm Test:  Exothermic temperature testing was conducted with a K-type 
thermocouple (Omega, Stamford, CT).  A Delrin! washer (McMaster-Carr, Aurora, OH) 
was first affixed to a glass slide with lab tape.  Then, the thermocouple was slightly bent 
to place the tip within the Delrin! washer without touching the glass slide and secured 
with lab tape such that the tip was in the center of the washer.  The silorane material was 
mixed with initiators and then mounded onto the thermocouple tip using a glass rod to 
ensure that the tip was completely covered with composite (~ 0.125 g).  A data logger 
(OM-PLTC, Omega Engineering Inc., Stamford, CT) was used to collect temperature 
readings from the thermocouple at 1 Hz for 30 min post-light initiation.  The maximum 
temperature was determined from this test.   
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Flexural Strength and Flexural Modulus:  The resins were injected into 
borosilicate glass tubes (VitroCom, Mountain Lakes, NJ) coated with a silicone spray 
mold release (Mark V Laboratory, East Granby, CT).  The specimens were irradiated 
with a dental lamp for two min on the top of the samples (three consecutive regions at 40 
s apiece) and for 40 s on the bottom in a scanning motion.  The samples were removed 
from the glass and yielded beams that were 25 mm x 2 mm x 2 mm, as per ISO 
specification 4049.55  The beams were stored at room temperature (23 ± 1 °C) for 24 h 
and then tested mechanically.  The beams were placed on four-point bend fixture with a 
support span of 20 mm on a mechanical tester (Instron 5967, Norwood, MA).   The 
samples were loaded at a displacement rate of 3.7 mm/min until failure.  Flexural strength 
and flexural modulus of elasticity were calculated using the resulting stress-strain curve. 
Degree of Conversion (DC):  Fourier Transform Infrared Spectroscopy (FTIR) 
was used to determine the degree of conversion of LCSM by comparing the change in a 
stretch associated with silorane ring-opening polymerization (883 cm-1 representative of 
an epoxide ring opening) to standard (one that remained unchanged upon polymerization; 
the 1257 cm-1 of the Si-O bond in CYGEP ring structure).  The peak ratios were then 
calculated.  Using lab tape, a delrin washer was affixed to the Attenuated Total 
Reflectance (ATR) accessory.  Approximately 0.1 g of material was placed into the ring 
that was centered over the ATR crystal.  Before curing the resin, one baseline spectrum 
was collected.  The samples were irradiated with a dental lamp for two min from a 
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distance of 3 mm.  Spectra were collected every 30 s, during the two-min light irradiation 
and continued at this frequency for 10 min post initial light irradiation.  Spectra were 
collected every 3.3 min from 10 – 20 min and every 5 min from 21 – 30 min post initial 
light irradiation.  The resulting degree of conversion curves for the samples yielded the 
rate of cure and the amount of unpolymerized monomer. 
 
Biocompatibility: 
LCSM Discs:  Polymer discs were prepared the day of the assay by polymerizing 
~80 mg of material in a Delrin! ring mold affixed to a glass slide with lab tape. Discs 
were light cured using a dental lamp at 40-s increments for a total of 2 min.  The 
polymerized discs were removed from the molds and sterilized using UV light for a total 
of two h (one h per side) in a laminar hood.  
Chemical Cure and P2 Discs:  Polymer discs were prepared the day before the 
assay by polymerizing ~80 mg of material in a Delrin! ring mold affixed to a glass slide 
with lab tape. The light cured samples were irradiated with a dental lamp at 40-s 
increments for a total of 2 min.   The chemically cured samples were placed in the rings 
and allowed to polymerize.  All samples were allowed to dark cure overnight.   On the 
day of the assay, the polymerized discs were removed from the molds and sterilized using 
UV light for a total of two h (one h per side) in a laminar hood. 
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Trypan Blue Assay:  The polymerized and sterilized discs were placed into 48-
well plate (n=3-4) and pre-washed in growth media for one-h at 35 °C/5% CO2. The 
wash media was discarded and replaced with 2 x 104 MLO-A5 cells/0.5 mL. After 24 h 
and 48 h of incubation, cell viability and proliferation were measured using the trypan 
blue method.60  
Leachables:  Discs were prepared as stated previously and used to test the effect 
of leachables on MLO-A5 cells.  The leachables were extracted from the polymer 
samples by incubating the discs for 24 h in culture media with serum. After 24 h, the 
extracts were transferred to a monolayer of MLO-A5 cells (seeded the previous day). The 
cells were exposed to the extracts for 24 h, after which the cell viability was measured 
using the methyl thiazolyl tetrazolium (MTT) assay.60  The cell viability was determined 
by measuring the optical density of the purple formazan produced by the enzymatic 
transformation of tetrazolium salt (MTT) by viable cells.  
 
Pull Out Tests: 
Ex Vivo:  All P2 samples were prepared as described previously.  The material 
was placed in a dental syringe, which was used to deliver the material into an excised rat 
femur. Then, a titanium rod (22 mm long and 1.5 mm in diameter) was inserted into the 
femur with the material.   The femur was imbedded in the holder with dental cement.  
The samples were stored in a humidified incubator for 24 h and tested biomechanically.  
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Commercially available bone cement samples were prepared per the standard instructions 
and used as a control.   
Mimic:  P2 samples were prepared as previously stated.  The material was placed 
in dental syringes, which was used to deliver the material into plastic tubing (3 mm 
diameter), which was pre-scored with holes that had been secured into a cut centrifuge 
tube with dental cement.  Then, a titanium rod (22 mm long and 1.5 mm in diameter) was 
inserted into the tube with the material.  The samples were kept in a humidified incubator 
for 24 h and tested biomechanically.   Commercially available bone cement samples were 
prepared per the standard instructions and used as a control.   
In Vivo Rat Studies: 
Sterilization:  On the day before surgery, SilMix, filler, and mixing cups were 
sterilized in a UV cabinet for 4 h.  All paper towels, spatulas, and petri dishes were 
autoclaved in the animal facility prior to the surgery.  The balance, speed mixers, mixing 
baskets, and chemicals (PIH, CPQ, and EDMAB) were transported to the animal facility 
where they were sterilized by the animal facility staff.  All paper towels, spatulas, and 
petri dishes were autoclaved in the animal facility prior to the surgery.   
In Vivo – regular: There previously described P2 sample was placed in a dental 
syringe.  The rats were anesthetized and operated on under aseptic condition. In short, the 
knees were exposed, and a hole was drilled between the femoral condyles and into 
intramedullary canal. The bone marrow was disrupted, and the marrow cavity was 
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irrigated and filled with the biomaterial. A titanium implant (22 mm long and 1.5 mm in 
diameter) was inserted. The capsule and skin were sutured.  The rats were then sacrificed 
at a specified time point, and the femur with the implant was recovered.  The excised 
femurs were then imbedded in the holder using dental cement and allowed to set for a 
time between 30 min and 24 h and tested biomechanically. Any control and commercially 
available bone cement was also tested under the same conditions. 
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APPENDIX B 
CHEMICAL INITIATION TABLE OF ACIDS AND INHIBITORS 
 
 
 
Acid wt % Runs Gillmore Needle Time 
Hydrochloric Acid    
2.0 2 Failed 8 h 
5.0 3 Failed 8 h 
10.0 2 Failed 8 h 
14.0 1 Failed 8 h 
18.0 1 Failed 8 h 
Acetic Acid    
5.0 2 Failed 8 h 
Phosphoric Acid     
7.8 2 Failed 8 h 
Sulfuric Acid      
8.0 2 Failed/Brittle   !!
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Acid wt % Runs Gillmore Needle Time 
Hydrobromic Acid     
7.5 1 Failed 8 h 
Hydroiodic Acid     
6.0 1 Failed 8 h 
Trichloroacetic Acid     
9.0 2 Failed 8 h 
Trifluoroacetic Acid     
7.0 2 Failed 8 h 
p-Toluenesulfonic Acid (pTSA)    
11.5 2 Failed 8 h 
Aluminum Chloride     
13.0 2 Failed 8 h 
Tin (IV) Chloride     
7.4 2 Failed 8 h 
Pentafluoropropionic Acid     
4.0 1 Failed 8 h 
15.0 1 Failed 8 h !
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Acid wt % Runs Gillmore Needle Time 
Pentafluoropropionic Acid     
18.0 1 Failed 8 h 
Triflic Acid      
2.0 1 Failed/Brittle   
4.0 1 Failed/Brittle   
Hexafluorophosphoric Acid (HFPA)    
2.0 4 Passed 2 min 
2.5 5 Passed 1 min 
4.0 2 Passed 30 sec 
4.6 2 Passed 30 sec 
5.0 10 Passed 30 sec 
Acetic Acid:HFPA     
2.0 : 4.8 2 Failed 1 h 
2.0 : 4.9 1 Failed 1 h 
1.2 : 2.8 2 Passed 0.75 h 
1.2 : 3.0 2 Failed 1 h 
1.0 : 3.2 3 Passed 1 h !
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Acid wt % Runs Gillmore Needle Time 
Acetic Acid:HFPA     
0.8 : 3.1 1 Passed 0.75 h 
1.2 : 5.0 1 Failed/poly in cup   
0.6 : 3.5 2 Failed/poly in cup   
1.2 : 2.7 2 Passed 2 days 
1.1 : 4.5 2 Failed/poly in cup   
1.1 : 3.4 2 Passed 2 days 
0.8 : 2.7 2 Passed 2 days 
2.3 : 2.5 1 Failed 1 h 
3.0 : 2.8 2 Failed 1 h 
3.1 : 2.1 2 Failed 1 h 
1.0 : 3.0 1 Failed 1 h 
0.8 : 3.8 1 Passed 1 day 
1.3 : 4.8 1 Passed 1 day 
1.6 : 3.8 1 Passed 1 day 
1.1 : 3.6 1 Passed 1 day 
1.1 : 3.5 1 Passed 2 days !
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Acid wt % Runs Gillmore Needle Time 
Acetic Acid:HFPA     
1.1 : 5.1 1 Failed/Powder   
1.2 : 4.1 1 Failed/poly in cup   
1.2 : 3.2 1 Passed 2 days 
1.3 : 2.6 1 Failed 1 day 
PIH:Phosphoric Acid     
3.05:5.37 1 Failed 2 h 
1.60:2.24 3 Failed 2 h 
3.15:2.21 3 Failed 2 h 
3.15:2.21 2 Failed 1 h 
0.65:1.63 2 Failed 2 h 
0.64:3.21 2 Failed 2 h 
0.63:5.03 2 Failed 3 h 
0.62:6.21 2 Failed 4 h 
3.17:1.59 2 Failed 2 h 
3.13:3.13 2 Failed 2 h 
3.07:4.90 2 Failed 2 h !
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Acid wt % Runs Gillmore Needle Time 
PIH:Phosphoric Acid     
3.02:6.29 2 Failed 2 h 
4.68:1.56 2 Failed 1 h 
4.62:3.08 2 Failed 1 h 
4.35:8.70 2 Failed 5 h 
8.33:8.33 2 Failed 5 h 
2.90:10.14 2 Failed 3 h 
4.23:11.27 2 Failed 2 h 
4.75:23.95 1 Failed/Powder   
1.60:2.24 2 Failed 3 h 
1.97:2.85 2 Failed 3 h 
2.23:2.23 2 Failed 6 h 
2.98:2.03 2 Failed 6 h 
1.60:2.30 4 Failed 5 h 
1.60:2.43 4 Failed 22 h 
2.97:2.21 4 Failed 5 h 
2.93:3.26 4 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
PIH:Phosphoric Acid     
1.60:4.70 4 Failed 4 h 
2.98:2.03 4 Passed* 22 h 
Phosphoric Acid     
3.23 2 Failed 3 h 
6.42 2 Failed 3 h 
5.06 2 Failed 3 h 
9.25 1 Failed 3 h 
1.64 2 Failed 3 h 
10.44 2 Failed 3 h 
11.76 2 Failed 2 h 
25.00 1 Failed/Powder   
PIH:Phosphoric Acid:HFPA     
3.13:2.19:0.63 1 Failed/Powder   
1.60:1.92:0.45 1 Failed/polym in cup   
0.45:1.95:0.13 1 Failed 1 h 
0.65:1.97:0.42 1 Failed 6 h !
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Acid wt % Runs Gillmore Needle Time 
PIH:Phosphoric Acid:HFPA     
0.65:1.94:0.58 1 Failed 6 h 
1.19:1.93:0.42 1 Failed 5 h 
1.19:1.93:0.61 1 Failed/gelled in cup   
1.51:1.95:0.42 1 Failed 2 h 
1.51:1.95:0.45 1 Failed 4 h 
1.50:2.05:0.45 1 Failed 1 h 
1.19:2.05:0.45 1 Failed 2 h 
1.19:1.96:0.45 1 Failed 2 h 
Phosphoric Acid:TiCl4    
3.77:2.26 1 Failed 8 h 
2.57:2.92 1 Failed 8 h 
3.18:3.25 1 Failed 8 h 
3.94:2.49 1 Failed 8 h 
Water:TiCl4    
0.31:3.54 1 Failed 8 h 
0.29:3.03 1 Failed 8 h !
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Acid wt % Runs Gillmore Needle Time 
Water:TiCl4    
1.12:2.95 1 Failed 8 h 
1.14:3.08 1 Failed 8 h 
TiCl4    
6.50 1 Passed, smoking gel 1 h 
2.87 1 Failed 8 h 
0.67 1 Failed 8 h 
0.85 1 Failed 8 h 
2.03 1 Failed 8 h 
2.82 1 Failed 8 h 
3.22 1 Failed 8 h 
PIH:TiCl4     
2.30:0.72 1 Failed/Powder   
0.34:0.67 1 Failed/Powder   
0.13:0.68 1 Failed 5 h 
0.16:0.96 1 Failed 5 h 
0.24:1.45 1 Failed 5 h !
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Acid wt % Runs Gillmore Needle Time 
PIH:TiCl4     
0.23:2.10 1 Failed 5 h 
0.26:2.06 1 Failed 5 h 
0.67:0.74 1 Failed/Powder   
0.26:3.87 1 Failed/Powder   
Phosphoric Acid:Triflic Acid     
1.92:2.22 1 Failed 8 h 
Phosphoric Acid:pTSA     
2.29:2.29 1 Failed 8 h 
Phosphoric Acid:Trichloroacetic Acid     
2.54:2.25 1 Failed 8 h 
Phosphoric Acid:Trifluoroacetic Acid     
2.56:3.59 1 Failed 8 h 
2.21:2.87 1 Failed 8 h 
PIH:Phosphoric Acid:pTSA     
1.56:18.69:1.87 1 Failed 8 h !!!
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Acid wt % Runs Gillmore Needle Time 
PIH:Phosphoric Acid:Trichloroacetic Acid     
1.86:2.48:2.59 1 Failed 8 h 
PIH:Phosphoric Acid:Trifluoroacetic Acid     
1.85:2.53:3.06 1 Failed 8 h 
2.17:2.17:2.57 1 Failed 8 h 
2.32:2.32:2.32 1 Failed 8 h 
2.16:2.66:2.53 1 Failed 8 h 
2.13:3.96:2.56 1 Failed 8 h 
2.17:2.48:2.54 1 Failed 8 h 
PIH:Trifluoroacetic Acid     
1.62:0.97 1 Failed 8 h 
1.92:2.05 1 Failed 8 h 
Phosphoric Acid:Ethyl Triflate     
3.46:1.07 1 Failed 5 h 
3.35:3.33 1 Failed 5 h 
Ethyl Triflate     
0.36 1 Failed 8 h !
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Acid wt % Runs Gillmore Needle Time 
Ethyl Triflate     
0.71 1 Failed 8 h 
6.07 1 Failed 8 h 
11.39 1 Failed 8 h 
Potassium t-butoxide     
2.98 1 Failed 24 h 
**Pyridine:HFPA    
1.2:5.0 1 Failed 0.5 h 
1.4:5.5 1 Failed 0.5 h 
2.7:6.3 1 Failed 0.5 h 
4.1:5.3 1 Failed 0.5 h 
2.3:8.3 1 Failed 0.5 h 
2.0:8.6 1 Failed 0.5 h 
2.1:9.3 1 Failed 0.5 h 
4.6:6.9 1 Failed 0.5 h 
2.6:9.3 1 Failed 0.5 h 
1.9:10.2 1 Failed 0.5 h !
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Acid wt % Runs Gillmore Needle Time 
**Pyridine:HFPA    
2.0:10.5 1 Failed 0.5 h 
2.3:11.1 1 Failed 0.5 h 
Pyridine:AA:HFPA    
2.6:1.4:5.9 1 Failed 0.5 h 
4.4:2.2:6.6 1 Failed 0.5 h 
3.1:2.6:9.4 1 Failed 0.5 h 
2.0:4.2:18 1 Failed 0.5 h 
BHT:HFPA     
0.9:3.6 1 Failed/polym in cup   
4.6:2.3 1 Failed 0.5 h 
5.7:2.8 1 Failed 0.5 h 
5.8:4.8 1 Failed/polym in cup   
9.1:3.3 1 Failed 0.5 h 
13.0:3.0 1 Failed 0.5 h 
16.4:1.8 1 Failed 0.5 h 
28.6:2.5 1 Failed 0.5 h !
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Acid wt % Runs Gillmore Needle Time 
BHT:AA:HFPA     
2.3:2.3:4.0 1 Failed/polym in cup   
3.3:2.7:3.5 1 Failed 0.5 h 
12-crown-4:HFPA     
2.6:4.6 1 Failed/polym in cup   
3.2:5.7 1 Failed 0.5 h 
8.7:4.4 1 Failed 0.5 h 
7.1:6.0 1 Failed 0.5 h 
8.6:5.7 1 Failed/polym in cup   
18.3:3.9 1 Failed 0.5 h 
12-crown-4:AA:HFPA    
4.4:6.1:8.4 1 Failed 0.5 h 
triethyamine:HFPA    
0.4 : 4.1 1 Failed 0.5 h 
3.6 : 1.9 1 Failed 0.5 h 
1.0 : 5.3 1 Failed 0.5 h 
1.4 : 9.4 1 Failed 0.5 h !
 204 
-./0I!
Acid wt % Runs Gillmore Needle Time 
triethyamine:HFPA    
1.7 : 9.2 1 Failed 0.5 h 
3.1 : 12.2 1 Failed 0.5 h 
7.8 : 8.6 1 Failed 0.5 h 
triethyamine:AA:HFPA    
0.7:2.6:7.3 1 Failed 0.5 h 
0.7:3.7:8.5 1 Failed 0.5 h 
3.7:5.2:8.2 1 Failed 0.5 h 
Acetonitrile:HFPA    
2.5 : 2.3 1 Failed 0.5 h 
1.5 : 8.2 1 Failed 0.5 h 
3.1 : 19.6 1 Failed 0.5 h 
Acetonitrile:AA:HFPA    
1.6:4.3:2.3 1 Failed 0.5 h 
1.7:7.7:1.8 1 Failed 0.5 h 
1.6:2.3:9.3 1 Failed 0.5 h 
1.4:8.9:5.0 1 Failed 0.5 h !
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Acid wt % Runs Gillmore Needle Time 
Acetonitrile:AA:HFPA    
3.9:5.5:11.2 1 Failed 0.5 h 
3.2:15.3:2.2 1 Failed 0.5 h 
3.0:15.4:2.2 1 Failed 0.5 h 
p-nitroaniline:HFPA      
1.5:6.2 1 Failed/polym in cup   
7.3:3.9 1 Failed 0.5 h 
4.1:9.1 1 Failed 0.5 h 
3.7:9.0 1 Failed/polym in cup   
5.4:17.8 1 Failed 0.5 h 
2,6-dinitroaniline:HFPA     
4.7:2.3 1 Failed/polym in cup   
4.6:2.5 1 Failed/polym in cup   
15.1:3.4 1 Failed/polym in cup   
phenylenediamine:HFPA    
3.6:4.3 1 Failed 0.5 h !!!
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Acid wt % Runs Gillmore Needle Time 
2,4-dinitroaniline:HFPA    
3.7:3.2 1 Failed/polym in cup   
Sulfanilamide:HFPA     
4.0:6.2 1 Failed/polym in cup   
2-aminopyridine:HFPA    
1.0:4.0 1 Failed 0.5 h 
1.3:4.3 1 Failed 0.5 h 
2.2:5.5 1 Failed 0.5 h 
4.0:4.5 1 Failed 0.5 h 
0.9:8.3 1 Failed 0.5 h 
2.0:7.6 1 Failed 0.5 h 
2.0:7.7 1 Failed 0.5 h 
1.8:7.9 1 Failed 0.5 h 
1.8:8.1 1 Failed 0.5 h 
1.8:10.1 1 Failed 0.5 h 
1.8:10.5 1 Failed 0.5 h 
3.5:8.9 1 Failed 0.5 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:HFPA    
1.9:10.8 1 Failed 0.5 h 
3.4:10.5 1 Failed 0.5 h 
3.4:10.6 1 Failed 0.5 h 
1.8:14.8 1 Failed/polym in cup   
1.3:14.1 1 Failed/polym in cup   
2-aminopyridine:AA:HFPA    
4.66:1.37:8.53 1 Failed 4 h 
3.97:2.92:5.02 1 Failed 4 h 
2.58:1.88:7.39 1 Failed 4 h 
3.43:2.17:8.12 1 Failed 4 h 
3.89:1.72:8.35 1 Failed 4 h 
4.30:1.36:9.16 1 Failed 4 h 
4.38:1.57:9.33 1 Failed 4 h 
4.04:2.02:9.21 1 Failed 4 h 
4.01:1.52:9.26 1 Failed 4 h 
3.98:1.55:11.11 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
3.46:2.11:9.80 1 Failed 4 h 
3.49:2.26:10.20 1 Failed 4 h 
3.47:2.09:9.81 1 Failed 4 h 
3.46:2.08:9.83 1 Failed 4 h 
3.46:2.25:9.84 1 Failed 4 h 
3.33:2.12:9.79 1 Failed 4 h 
3.44:2.13:10.35 1 Failed 4 h 
3.43:2.51:10.39 1 Failed 4 h 
3.45:2.10:10.16 1 Failed 4 h 
3.43:2.14:10.01 1 Failed 4 h 
3.46:2.26:10.36 1 Failed 4 h 
3.45:2.27:10.18 1 Failed 4 h 
3.67:2.20:10.55 1 Failed 4 h 
3.42:2.25:10.71 1 Failed/gelled in cup   
3.46:2.26:10.54 1 Failed 4 h 
3.45:2.23:10.69 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
3.47:2.29:10.15 1 Failed 4 h 
3.47:2.33:10.70 1 Failed 4 h 
3.62:2.36:6.36 1 Failed 4 h 
3.47:2.07:10.38 1 Failed 4 h 
3.41:2.12:10.53 1 Failed/gelled in cup   
3.41:2.18:10.35 1 Failed/gelled in cup   
3.33:2.07:12.72 1 Failed/gelled in cup   
3.28:2.15:13.05 1 Failed/polym in cup   
3.38:2.32:10.36 1 Failed 4 h 
3.41:2.32:10.39 1 Failed 4 h 
3.41:2.55:10.83 1 Failed 4 h 
3.54:2.29:10.40 1 Passed/ gelled in cup 10 min 
3.65:2.27:10.98 1 Failed/gelled in cup   
3.72:2.36:10.42 1 Failed/gelled in cup   
3.81:2.44:10.28 1 Failed 4 h 
3.83:2.38:9.81 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
3.85:2.12:10.06 1 Failed 4 h 
3.91:2.33:10.43 1 Failed/smoking gel    
3.97:2.39:10.14 1 Failed/gelled in cup   
4.01:2.37:9.92 1 Failed 4 h 
4.36:2.19:10.12 1 Failed 4 h 
4.30:2.44:9.86 1 Failed 4 h 
4.59:1.95:9.83 1 Failed 4 h 
3.40:2.51:11.07 1 Failed/polym in cup   
3.41:2.55:10.83 1 Failed 4 h 
3.46:2.60:10.71 1 Failed 4 h 
3.53:2.67:10.97 1 Failed 4 h 
3.66:2.66:10.37 1 Failed 4 h 
3.86:2.15:9.95 1 Failed 4 h 
3.78:2.67:9.96 1 Failed 4 h 
3.78:2.69:10.13 1 Failed 4 h 
3.82:2.20:10.30 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
3.32:2.57:10.94 1 Failed 4 h 
2.80:2.20:10.11 1 Failed 4 h 
2.86:2.13:9.81 1 Failed 4 h 
2.84:2.28:10.25 1 Failed 4 h 
2.84:2.36:10.19 1 Failed 4 h 
2.85:2.29:10.02 1 Failed 4 h 
2.86:2.29:9.87 1 Failed 4 h 
2.85:2.40:9.83 1 Failed 4 h 
2.85:2.54:9.84 1 Failed 4 h 
2.69:2.41:9.88 1 Failed 4 h 
2.84:2.45:10.08 1 Failed 4 h 
2.69:2.29:9.96 1 Failed 4 h 
2.96:2.41:9.88 1 Failed 4 h 
2.69:2.27:9.84 1 Failed 4 h 
2.69:2.43:9.90 1 Failed 4 h 
2.58:2.41:9.79 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
2.68:2.43:10.03 1 Failed 4 h 
2.58:2.41:9.86 1 Failed 4 h 
2.55:2.49:9.85 1 Failed 4 h 
2.69:2.52:9.84 1 Failed 4 h 
2.40:10.16 1 Failed/gelled in cup   
2.58:2.44:9.88 1 Failed 4 h 
2.68:2.43:9.95 1 Failed/gelled in cup   
2.71:2.51:9.86 1 Failed/gelled in cup   
2.72:2.44:9.75 1 Failed/gelled in cup   
2.67:2.50:9.61 1 Failed/gelled in cup   
2.68:2.49:9.95 1 Failed/gelled in cup   
2.70:2.50:9.49 1 Failed/gelled in cup   
2.74:2.48:8.99 1 Failed/gelled in cup   
2.88:2.65:8.78 1 Failed/gelled in cup   
2.76:2.47:7.41 1 Failed 4 h 
2.77:2.57:8.07 1 Failed 4 h !
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Acid wt % Runs Gillmore Needle Time 
2-aminopyridine:AA:HFPA    
2.76:2.56:8.31 1 Failed 4 h 
2.74:2.45:8.19 1 Failed 4 h 
2.74:2.51:8.13 1 Failed 4 h 
2.74:2.52:8.13 1 Failed 4 h 
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